HaematologyReport PDF

2001-2011
Department of HAEMATOLOGY
10 YEAR RESEARCH REPORT
South Eastern Sydney Local Health District
HAEMATOLOGY
Centre for Thrombotic and

Bleeding Disorders
Research
Clinical Trials Unit
SEALS
Cancer Care Centre
St George Clinical School

UNSW
St George Hospital --- Kogarah
Sutherland Hospital --- Caringbah

ii
SESLHD – SGSHHS– DEPARTMENT OF HAEMATOLOGY
ii
i
SESLHD – SGSHHS– DEPARTMENT of HAEMATOLOGY
INTRODUCTION
The Department of Haematology provides clinical and laboratory haematology services
for the southern sector of the South Eastern Sydney Local Health District.
The clinical unit provides comprehensive care to patients with a broad spectrum of
benign and malignant haematological disorders including anaemias, leukaemias,
lymphomas, myelomas and disorders of haemostasis or thrombosis.
The unit also provides high dose therapy and autologous stem cell transplantation. Our
haematologists manage both general haematological and haemato-oncological
conditions.
The Department of Haematology is accredited by the Royal College of Pathologists of

Australasia for supervised registrar training in Haematology, and actively participates in
training junior laboratory staff. The Department is a centre of excellence catering for the
diagnostic, clinical, research and teaching activities of the SESLHD.
Clinical Excellence - Research Excellence - Laboratory Excellence
Principal Investigators are supported by a team of physicians, scientists and research

staff dedicated to laboratory and clinical research.
The SEALS Haematology Laboratory is NATA AS4633 (ISO 15189) and AS/NZS ISO
9001:2000 accredited and provides a range of laboratory services in haematology
including automated blood cell analysis and morphology, bone marrow examination,
flow cytometry, routine and special coagulation assays, transfusion medicine and
haemopoietic stem cell transplantation. An area reference services is provided for B12
and folate assays, intrinsic factor antibodies, whole blood aggregation and heparin
induced anti-platelet antibodies. A state wide reference service is provided for drug-
dependent and autoimmune anti-platelet antibodies.
The Clinical Trials Unit (CTU) has been operating since July 1993. The Unit is co-located
in a dedicated trial unit space alongside the Cancer Care Centre in the W R Pitney
Building. The unit has a staff of clinical research co-coordinators and research nurses
reporting to a clinical trials unit manager. We operate from two purpose-built clinical
trials units over two hospitals. In 2007, the Centre for Thrombotic and Bleeding
Disorders Research was formed, delivering investigator-led research primarily into VTE
and ITP. In 2011, an International ITP registry was set up with St George Hospital as the
co-ordinating centre for potentially hundreds of research sites worldwide.
The Haematology Research Laboratory (Department of Medicine) operates from the St

George Research Building, and within the SEALS complex of laboratories. The Basic and
Translational Research Laboratory in the St George Clinical School has a history of
excellence, publishing original research in high impact international science/medical
journals such as Science Translational Medicine, BLOOD, Molecular and Cellular Biology,
Department of Haematology Research Report 2001-2011 Version 1

ii
New England Medical Journal, Lancet, and Cancer Research. The Haematology Research
Laboratory is and has been funded by Category 1 grants including NHMRC
project/program grants (continuously since 1990; 4 renewals of NHMRC Program
grants), ARC, NHF, Commonwealth AIDS Research grant and international grants
including Singapore National Medical Research Council grant.
SEALS laboratories maintain laboratory services, which includes laboratory research

activities.
Both St George Hospital and Sutherland Hospital facilities are ideally positioned for
conducting research utilising both inpatient and outpatient based populations.
Our Mission Statement:
Making a difference in Healthcare through quality

research
All clinical research is conducted in accordance with the:
NHMRC National Statement on Ethical Conduct in Human Research
ii
iii
FROM THE DIRECTOR OF HAEMATOLOGY
The Haematology Department at St George and Sutherland

Hospitals has an extensive record of research, and this report
demonstrates the depth of research for the last 10 years.
Programs encompass basic science, cardiovascular disorders and
translational research with a focus on platelets; through to the
clinical research unit, which has grown dramatically in the last 10
years.
It takes a team to produce good research results, and I am proud of our contributions to
the scientific community, and recommend this report to you.
Professor Beng Hock Chong.

iv
TABLE OF CONTENTS
INTRODUCTION ..................................................................................................................................i
FROM THE DIRECTOR OF HAEMATOLOGY ....................................................................................... iii
TABLE OF CONTENTS........................................................................................................................ iv
ST GEORGE/SUTHERLAND HOSPITALS AND HEALTH SERVICES ....................................................... 1
HAEMATOLOGY ORGANISATIONAL STRUCTURE ............................................................................. 2
HAEMATOLOGISTS AND RESEARCH INTEREST................................................................................. 3
RESEARCH AREAS ............................................................................................................................. 8
CENTRE FOR THROMBOTIC AND BLEEDING DISORDERS RESEARCH ..................................... 8
INITIATION OF CTBR ITP INTERNATIONAL REGISTRY 2011.................................................. 10
HAEMATOLOGY CLINICAL TRIALS UNIT ............................................................................... 12
HAEMATOLOGY TRIALS 1997-2011 ..................................................................................... 13
SEALS LABORATORY ACTIVITIES .......................................................................................... 27
BASIC AND TRANSLATIONAL RESEARCH LABORATORY (St George Clinical School) ............ 28
RESEARCH GRANTS ........................................................................................................................ 33
COMMERCIAL FUNDING – CURRENTLY HELD BH CHONG: .................................................. 37
PUBLICATIONS................................................................................................................................ 39
BH CHONG ........................................................................................................................... 39
SH LEE .................................................................................................................................. 46
S RAMANATHAN .................................................................................................................. 48
SJ HO .................................................................................................................................... 48
F RONCOLATO ...................................................................................................................... 49
X BADOUX ............................................................................................................................ 50
P CHOI .................................................................................................................................. 51
N CHAPMAN ........................................................................................................................ 51
C HICKS................................................................................................................................. 51
R WONG ............................................................................................................................... 52
iv
v
S SMITH ................................................................................................................................ 52
R GEMMELL .......................................................................................................................... 52
J PERDOMO .......................................................................................................................... 53
PRESENTATIONS: SCIENTIFIC MEETINGS AND CONFERENCES ....................................................... 55
BH CHONG ............................................................................................................................ 55
SJ HO..................................................................................................................................... 59
X BADOUX ............................................................................................................................ 61
P CHOI .................................................................................................................................. 62
N CHAPMAN ......................................................................................................................... 63
R RISTUCCIA.......................................................................................................................... 63
C HICKS ................................................................................................................................. 63
S SMITH ................................................................................................................................ 64
R WONG ............................................................................................................................... 65
R GEMMELL .......................................................................................................................... 65
J PERDOMO .......................................................................................................................... 66
COMMUNITY ENGAGEMENT .......................................................................................................... 68

1
ST GEORGE/SUTHERLAND HOSPITALS AND HEALTH SERVICES
http://www.sesiahs.health.nsw.gov.au/sgh/
http://www.sesiahs.health.nsw.gov.au/tsh/

2
HAEMATOLOGY ORGANISATIONAL STRUCTURE

DEPARTMENT OF HAEMATOLOGY STRUCTURE
DIRECTOR: Beng CHONG
Medical Teams Nursing Research Laboratory Services
Centre for Thrombotic SEALS

and Bleeding Disorders Haematology
Professor Beng Cancer Care Centre
Research / Clinical Laboratory
Hock Chong (NUM: Lucy Burns )
Trials Unit (Manager: (Manager: Sudha
Roslyn Ristuccia) Pillai)
Dr Sundra Flow Cytology

4N Haematology SEALS Laboratories B12 / Folate
Ramanathan. (Senior Hospital
Ward (NUM: Research
Research (Professor
(Professor (SeniorTechnical
(Senior
(Staff Staff
Specialist) Scientist: Susan
Jennifer Rickard) Szu-Hee Lee) Lee)
Szu-Hee Officer: Karen Staff)
Specialist) Smith)
Clinical Nurse Basic and

Dr Fernando Blood Bank (Senior Main Laboratory
Consultants Translational Research
Roncolato (Staff Hospital Scientist: (Technical Officer:
(Haematology: Laboratory (Manager:
Specialist) Peter Loizou) Rema Nasr)
Nicole Goodman) Dr Jose Perdomo)
Clinical Nurse Bone Marrow Morphology

Consultants (Cancer Transplant (Senior Hospital
Dr Xavier Badoux
Outreach: Laboratory (Senior Scientist: Nella
(Staff Specialist)
Cassandra Hobbs / Hospital Scientist: Mangos and Nicole
Jo Cryer) Christine Wassell) Lewis)
Coagulation / Special Transfusion

Nurse Educator
Dr Shir-jing Ho Coagulation (Senior (Governance Co-
(Cancer Services:
(Staff Specialist) Hospital Scientist: ordinator: Patricia
Patricia Morris)
Rosalie Gemmell) Pillai)
Dr Amanda
Hugman (Staff
Specialist)
Professor Szu-Hee
Lee
2
3
HAEMATOLOGISTS AND RESEARCH INTEREST
Director of Haematology:
Professor Beng Chong, MBBS, PhD (Syd), FRCP (Glasgow),
FRACP, FRCPA
Professor (Conjoint), Department of Medicine, St George Clinical
School, University of New South Wales (UNSW).
Director, Clinical and Laboratory Haematology,
St George and Sutherland Hospitals and SEALS Central.
Member, UNSW Research Management Committee, Faculty of
Medicine
The St George Hospital,
Gray Street KOGARAH NSW 2217
AUSTRALIA
Sec: (612) 9113 2960
Fax: (612) 9113 3426
Email add: beng.chong@unsw.edu.au
His research ranges from basic science to translational and clinical research. Basic research
includes transcription regulation of platelet production and megakaryopoiesis, biology of
Oncogenes: Fli-1, GATA-1, PU-1 and FOG-1 and stem cell biology. Translational Research includes
mechanisms of and novel treatments for immune thrombocytopenias. Clinical research includes
prophylaxis and the treatment of venous thromboembolism and Immune thrombocytopenia.
Member of the Board of St George Medical research Foundation and Deputy Chair, Scientific
Advisory Committee, St George Medical research Foundation 2007-2012
NHMRC Project Grant assessment panel member 2008 and 2010
Member, Medical and Dental Appointments Advisory Committee, St George Hospital, Sydney
since 2001
Member of Clinical Council, St George Hospital, Sydney
Co-chair, Platelet Immunology, International Society of Thrombosis and Haemostasis
Vice-President, Australian Bid Committee, International Society of Thrombosis and Haemostasis,
(ISTH) and ISTH Congress 2019
Director, Centre for Thrombosis and Bleeding Disorders research
Chair of Steering committee, International ITP Registry
For more information visit:

http://med.unsw.edu.au/people/professor-beng-chong

4
Senior Medical Staff:
Professor Szu-Hee Lee, MBBChir, PhD, FRCPE, FRCPath, FRACP,
FRCPA
Senior Staff Specialist
Haematology Department
The St George Hospital
AUSTRALIA
Phone: (612) 9113 3427
Fax: (612) 9113 3942
Email: Szu-Hee.Lee@sesiahs.health.nsw.gov.au
Dr Lee is Senior Staff Specialist in Haematology at St George Hospital and Conjoint Professor,
School of Medical Sciences, University of New South Wales. Dr Lee supervises the diagnostic
morphology and transfusion services. His research interests are in laboratory and experimental
haematology.
Staff Specialists:
Dr Sundra Ramanathan, MBBS, FRACP, FRCPA

Staff Specialist Haematology
Haematology Department, The St George Hospital
AUSTRALIA
Phone: (612) 9113 2692 (Secretary: Claire Gore)
Fax: (612) 9113 3958
Email address: Sundra.Ramanathan@sesiahs.health.nsw.gov.au
Dr Ramanathan has an interest in haematological malignancies and is Medical Director of the

Bone Marrow Transplant Unit at St George Hospital. He is a Conjoint Lecturer with the University
of New South Wales.
4
5
Dr Shir-jing Ho, MBBS, FRACP, FRCPA

Cancer Care Centre, The St George Hospital
AUSTRALIA
Phone: (612) 9113 3425
Fax: (612) 9113 3942
Email: shir-jing.ho@sesiahs.health.nsw.gov.au
Dr Ho’s clinical research includes treatment of acute and chronic leukaemias and lymphoma, as
well as problems of thrombosis and haemostasis. She has a laboratory interest in haemostasis
and platelet disorders.
Dr Fernando Roncolato, B Med FRACP FRCPA

Department of Haematology
AUSTRALIA
Phone : (612) 9113 3851
Fax : (612) 9113 3958
Email add: Fernando.Roncolato@sesiahs.health.nsw.gov.au
Dr Roncolato has an interest in the management of lymphoproliferative disorders. He is a

Conjoint Lecturer in Medicine at the University of New South Wales. Dr Roncolato undertook
research in 2010/2011 at the Department of Haematopathology, University of Bologna, Italy,
examining the role of T-cell receptor gene rearrangement analysis in the diagnosis of T-cell
lymphomas.
Dr Amanda Hugman, MBBS, FRACP, FRCPA, MPhil

AUSTRALIA
Phone: (61-2) 9113 3851
Fax: (61-2) 9113 3942
Email add: Amanda.Hugman@sesiahs.health.nsw.gov.au
Dr Hugman has an interest in the management of malignant haematology and general

haematology, including iron disorders, thrombosis and haemostasis. She has laboratory research
experience in molecular aberrations in acute myeloid leukemias.

6
Dr Xavier Badoux, MBBS, FRACP, FRCPA

Senior Staff Specialist Haematology
AUSTRALIA
Phone: (612) 9113 3851
Fax: (612) 9113 3942
Email: Xavier.Badoux@sesiahs.health.nsw.gov.au
Dr Badoux is a clinical haematologist with a research interest in the treatment of

lymphoproliferative disorders. He is currently performing translational research in chronic
lymphocytic leukemia utilizing next-generation sequencing to identify recurrent mutations in
CLL. Dr Badoux is a Conjoint Lecturer in Medicine at the University of New South Wales.
Research Staff:
Senior research staff
Post –doctoral Scientists: José Perdomo, Feng Yan, Xing-Mai Jiang, Jim Fang
Research scientist: Zohra Ahmedi.
Scientific Staff:
Haematology Laboratory
Manager: Sudha Pillai; Deputy Manager: Susan Smith
Chief Scientists:
Laboratory Manager and Quality Representative: Sudha Pillai, BAppSc(Biomedical), MHA, AIMS
Senior Hospital Scientist Blood Bank: Peter Loizou, Path Tech Certificate, BAppSc (Biomedical)
Senior Hospital Scientist Flow Cytometry: Susan Smith, BAppSc (Biomedical)
Senior Hospital Scientist Coagulation and Special Coagulation: Rosalie Gemmell, BAppSc (Clinical
Biochemistry)
Senior Hospital Scientist Bone Marrow Transplant Lab: Dr. Christine Wassell, BSc, MSc, PhD
Senior Technical Officer B12/Folate: Karen Staff, Path Techniques, Associate Diploma
Senior Hospital Scientist in charge, Morphology: Nella Mangos, BAppSc (Biomedical), Nicole
Lewis, BSc, MPH
6
7
Clinical Trials Unit
Clinical Trials Unit Manager
Roslyn Ristuccia BSc DipCompSc MMedSc(ClinEpi)

Roslyn was the first research co-ordinator in Haematology clinical trials unit, starting in 1997, and has overseen the
growth and quality improvements since then. She has interests in epidemiology, the use of technology in clinical
research, and in quality management.
Clinical Trials Unit- Research Coordinators
Karina Chui RN (Research Nurse)

In 2001, Karina specialised in Haematology Oncology Nursing at St George Hospital. By 2008, Karina joined the
research unit undertaking Malignant Haematology research studies. She currently manages and coordinates multiple
Haematology malignant studies such as Myelodysplastic Syndrome, Non Hodgkin’s Lymphoma, Chronic Lymphocytic
Lymphoma as well as Polycythemia Vera/Essential Thrombocythemia.
Sarah Davidson RN (Research Nurse)

Sarah trained as a Registered Nurse at Sydney University. Sarah began her research experience managing sponsored
thrombosis trials, after which she moved into both sponsored and collaborative group malignant haematology
studies, specifically coordinating CML, lymphoma and myeloproliferative disorder studies. Sarah is currently the
Project Manager at the Coordinating Centre for an investigator driven global ITP Registry.
Lorraine King RN (Research Nurse)

Lorraine worked as a Research Nurse for the University of New South Wales School of Medicine before joining the
Clinical Research Unit based at Sutherland Hospital in 2008. Lorraine managed research studies in DVT prophylaxis
post hip and knee surgery, and then transferred to St George Hospital to work on a variety of malignant Haematology
disease registries and clinical trials on Mantle Cell Lymphoma, and CML.
Margaret Loizou BSc (Clinical Research Co-ordinator)

Margaret is an experienced Scientific Officer who joined the trials unit in 2004. Margaret has predominantly managed
and coordinated research studies in DVT and ITP. She also has research experience in malignant haematology research
studies which includes: Multiple Myeloma, Chronic Lymphocytic Leukaemia, Polycythemia Vera/Essential
Thrombocythemia.
Elena Simon Mendoza BMedSc (Clinical Research Co-ordinator)

Before joining the research unit in Aug 2009 Elena worked as a scientific officer for 4 years in the department of Seals
Pathology. Elena co-ordinates research studies in Venous Thromboembolism, as well as studies specialising in Heparin
Induced Thrombocytopenia and chronic myeloid leukaemia.
Kareen Fierro (Clinical Trials Assistant)

Kareen has been working at the St George Clinical Trials unit since 2009. Kareen is a liaison officer between Ethics,
RGO, Investigators and Sponsors.
(Note: These are our present staff as at time of going to press. We also wish to acknowledge the
contributions of the many other staff over the last 10 years who have since moved to positions
elsewhere.)

8
RESEARCH AREAS
CENTRE FOR THROMBOTIC AND BLEEDING DISORDERS RESEARCH
Centre for Thrombotic and Bleeding Disorders

Research
In 2007 the Centre for Thrombotic and Bleeding Disorders
Research Unit UNSW was established within St George by
Professor Beng H. Chong.
Mission: The Thrombosis and Bleeding Disorders Unit has been established to improve
Australian patient care by:
• Conducting cutting edge, well designed research into thrombosis and bleeding
disorders including its treatment and the medical management of patients with these
conditions
• Disseminating knowledge to patients, clinicians, students and other health care
professionals about this specialty.
This Unit is a collaboration between research teams resulting in expertise in basic science, drug
development, clinical research, community health, population health and health service
research as well as thrombosis and bleeding disorders research and education, thus ensuring
research excellence in clinical and translational research.
8
9
3
The following research projects have been carried out.
Protocol Study title Student / Staff Planned Planned

# Start finish
Objective 1: Improve VTE prophylaxis (Px) in hospitalised patients
CTBR Understanding facilitators, barriers and Steve Lazar Complete Publish
007B attitudes to VTE Px 2009 2010
CTBR Understanding when VTE Px is considered Bridget Josephs Feb 2010 Nov 2010
007C or could be considered to improve
compliance
CTBR VTE Prophylaxis in a rural hospital Bridget Josephs Complete Publish
007D 2010 2010
VTE risk assessment by nursing staff Bridget Josephs July 2010 Sept 2011
intervention - pilot
CTBR ACCP guideline validation – pilot study Mary Clarke Nov 2009 July 2010
007A
ACCP guideline validation (pending pilot Nicola Chapman Jan 2011 Dec 2011
results and ARC grant)
Testing Interventions to improve VTE px Nicola Chapman 2011 Dec 2011
rates
CTBR 011 Audit of surgical VTE Px implementation Jocelyn Aitken August November
2010 2010
NSW Health medication chart intervention Nicola Chapman August September
2010 2011
Objective 2: Determine if VTE prophylaxis (Px) is indicated in community based patients
CTBR-014 Retrospective study VTE incidence of heart Rima Mourad Feb 2010 Nov 2010
failure and respiratory failure in the
community
CTBR Prospective study of VTE incidence in Justin Friedman Feb 2011 Dec 2011
014A heart failure patients in the community
Objective 3: Optimise treatment of VTE patients

A VTE registry Roslyn Ristuccia 2007 Ongoing
CTBR VTE Pattern of Care study Mary Clarke 2008 Nov 2010
001A
CTBR Understand facilitators and obstacles to Tbd (awaiting student Tbd Tbd
001B optimal VTE management in the interest; HREC
community. approved)
CTBR 009 RCT of clexane vs warfarin for calf clots Jocelyn Aitken March 2012
2010
Objective 5: Improve treatment of Idiopathic thrombocytopenic purpure (ITP).
ITP registry Sarah Davidson/Beng Q3 2010 2012-2015
Chong
CTBR 003 Ginseng for ITP treatment Roslyn Ristuccia/Beng 2013 2014
Chong
Objective 6: Identify a treatment for patients with heparin-induced t’penia (HIT)
CTBR 005 Characterisation of HIT antibodies Sima / Nathalie / Feb 2009 2010
Arend /Zohra
RCT of lepirudin to fondaparinux Phil Choi Tbd Tbd
Objective 7: Drug induced thrombocytopenia

CTBR 008 Vancomycin and thrombocytopenia Nathalie / Elizabeth Feb 2009 2010
antibody incidence

10
INITIATION OF CTBR ITP INTERNATIONAL REGISTRY 2011
ITP is a bleeding disorder in which the immune system destroys the patient’s own platelets
causing depletion of platelets (blood cells involve in blood clot formation and prevent us from
bleeding). Without enough platelets, bleeding can occur and it
can range from mild bruising to severe and fatal haemorrhage.
In 2011, the Centre for Thrombosis and Bleeding Disorders

Research at St George Hospital, initiated an Investigator-led
International ITP Registry.
“A Multi-centre, prospective disease registry for adults

diagnosed with primary immune thrombocytopenia (ITP)
in international countries.”
Professor Beng H. Chong chairs the International Registry

Steering Committee which manages this registry.
Conducted and data managed from St George Hospital the
disease registry has garnered interest from more than 45
haematologists from across the Asia-Pacific, Middle Eastern
and South American regions including Australia, Japan,
Korea, India, China, Singapore, Turkey, Israel, Brazil.
10
11
As at December 2011, the Registry had the following active sites and recruitment:
Growing quickly, it is expected that in 2012 the registry will expand considerably across the
world.

12
HAEMATOLOGY CLINICAL TRIALS UNIT

The Clinical Trials Unit (CTU) has been operating since July 1993.
The Unit is co-located in a dedicated trial unit space alongside the
Cancer Care Centre in the W R Pitney Building.
The unit has a staff of clinical research co-coordinators and
research nurses reporting to a clinical trials unit manager. We
operate from two purpose-built clinical trials units over two
hospitals.
Both facilities are ideally positioned for conducting research, and utilising both inpatient and
outpatient based populations. The St George Clinical School, operating from St George Hospital,
is part of the University of New South Wales.
Over the last 10 years, the clinical trials unit has demonstrated huge growth. From 1 part-time
staff member running one study, we now have 7 co-ordinators, administration staff, and a
portfolio of over 30 active studies.
All aspects of our conduct are governed by quality standards and in compliance with relevant
regulations, hospital policy and current best practice.
St George Hospital is a member of the NSW Network of Haematology Clinical Research Sites.
Refer to our websites:
St George/Sutherland Haematology Clinical Trials Unit
NSW Network of Haematology Clinical Research Sites
Clinical Research Trials Conducted 2004 2005 2006 2007 2008 2009 2010 2011
Haematology Trials 11 12 14 24 20 28 28 30
There has been a consistent increase in the

number of trials conducted in haematology HAEMATOLOGY TRIALS CONDUCTED
since its early beginnings. The first studies 35
conducted in haematology were mainly 30
thrombosis and haemostasis studies,
25
contributing to the work done for the
approval of the new brands of oral 20
anticoagulants. 15
10
The Cancer Institute Grant awarded to
5
Haematology CTU in 2008 to employ an extra
clinical research co-ordinator was utilised to 0
2004 2005 2006 2007 2008 2009 2010 2011
increase the number of malignant
haematology studies being conducted. This increase has been sustained and improved upon. St
George Haematology CTU increased the total number of clinical research trials being conducted
to 30 in 2011.
12
13
HAEMATOLOGY TRIALS 2001-2011

14
14
15

16
16
17

18
18
19

20
20
21

22
22
23

24
24
25

26
26
27
SEALS LABORATORY ACTIVITIES
The laboratory is NATA AS4633 (ISO 15189) and AS/NZS ISO 9001:2000 accredited and provides
a range of laboratory services in haematology including automated blood cell analysis and
morphology, bone marrow examination, flow cytometry, routine and special coagulation assays,
transfusion medicine and haemopoietic stem cell transplantation.
An area reference services is provided for

intrinsic factor antibodies, whole blood
aggregation and heparin induced anti-platelet
antibodies.
A state wide reference service is provided for

drug-dependent and autoimmune anti-
platelet antibodies.
The Department of Haematology is accredited by the Royal College of Pathologists of Australasia

for supervised registrar training in Haematology, and actively participates in training junior
laboratory staff.
The Department is a centre of excellence catering for the diagnostic, clinical, research and
teaching activities of the SESLHD.

28
BASIC AND TRANSLATIONAL RESEARCH LABORATORY (St George Clinical School)
The Haematology Department of Medicine Research Laboratory conducts original research into
key aspects of haematopoiesis and blood diseases. As such, the laboratory works on two related
areas:
a) Basic research into gene and transcriptional regulation in

haematopoiesis (especially megakaryocyte development and
platelet production). This includes work on the molecular and
cellular mechanisms of cytopenic and other haematological
disease.
b) Translation Research into potential therapeutic strategies to

treat conditions such as heparin-induced thrombocytopenia,
thrombosis and immune thrombocytopenia.
Over the past 10 year this laboratory has made great progress in the understanding of the
genetic control of platelet production and cardiac cell development, particularly transcription
factor functions in regulation of these processes. For example we were the first to clone human
FOG2, a key cardiac transcript factor. In addition, significant progress has been made in the
understanding of the mechanisms of drug-induced thrombocytopenia and in the design of
potential therapies for heparin-induced thrombocytopenia and thrombosis.
Dr Jose Perdano Dr Feng Yan
Research Projects:
1. Transcriptional regulation in haematopoietic cells: understanding the basic genetic
programs that determine cell fate is essential for the design of novel therapeutic strategies.
The principal findings of this project are:
- ETS transcription factors in conjunction with kinase-mediated extracellular signalling
control the expression of GPIX, an essential platelet-specific receptor protein (1).
- Expression of the megakaryocyte/platelet-specific receptor GPVI is controlled by the
transcription factors GATA-1, Fli-1 and Sp1 (2)
28
29
- Activation of megakaryocyte-specific promoters depends on the nuclear import of the

transcription factor Fli-1 (3)
- A nuclear targeting sequence in the transcription factor PU.1 is required for the control
of myeloid genes (4)
- P45-NF-E2 mediates the enhancement of megakaryocyte differentiation and platelet
production in vivo (5)
- A nuclear localization signal in the transcription factor p45-NF-E2 is essential for platelet
production (6)
2. Drug-induced thrombocytopenia: A variety of drugs commonly used in the clinic can result
in the production of drug-dependent antibodies that cause a marked drop in platelet
numbers, hence leading to bleeding and potentially serious internal haemorrhage. It’s
important to elucidate the mechanisms of this disease in order to improve patient care. The
main findings of the Medicine Lab in this respect include:
- Fine mapping of the binding sites of quinine-dependent antibodies on the platelet
receptor complex GPIb/IX (7)
- Development of a novel mouse model to evaluate drug-induced antibody platelet
destruction in vivo and to test the efficacy of treatments (8)
- Finding that drug-induced antibodies also cause a drop in platelet production by
damaging platelet-producing cells (megakaryocytes) (9)
3. Heparin-induced thrombocytopenia/thrombosis: Heparin is widely used as an anti-

coagulant in clinical settings. One of the serious side effects of heparin use is the occurrence
of an immune reaction in some patients. This gives rise to a heparin-dependent antibody
that attacks platelets causing platelet destruction and thrombus formation. The following
findings have emerged from this research area:
- Identification of mutations that enhance the binding of pathogenic antibodies to platelet
factor. This is important as a diagnostic tool, since there is a pressing need to
differentiate between harmless heparin-dependent antibodies (non-pathogenic) and
those that cause platelet damage. Development of a mini-antibody that prevents
platelet destruction by protecting the platelets from the antibody-mediated attack.
4. Cardiac transcription factors and cardiac stem cells. Some key transcription factors involved
in blood development have counterpart in the cardiac system, these include FOG-2 and
GATA-4. Some time ago our laboratory cloned one of these factors, FOG-2 (Holmes et al,
hFOG-2, a Novel Zinc Finger Protein, Binds the Co-repressor mCtBP2 and Modulates GATA-
mediated Activation, JBC, 1999). Some of the key findings from this project include:
- Identification of the mechanisms mediating nuclear trafficking of GATA-4 (10)
- Establishment of a murine myocardial ischemic model to analyse the migration of
cardiac stem cells to sites of injury (11, 12)
- Finding that FOG-2 is modulated by a post-translational modification (SUMOylation).
This modification controls the magnitude on FOG-2 activity on its target genes

30
Collaborations
The Haematology Department of Medicine Research Laboratory collaborates with a number of
researchers. Some of these projects include:
- Collaboration in nuclear localization studies with the laboratory of Prof. David Jans at
Monash University (6)
- With Prof. Merlin Crossley’s lab at Sydney University on transcriptional regulation in blood
cells (13, 14)
- With Prof. Miles Davenport at the Centre for Vascular Research, UNSW regarding
mathematical models of platelet destruction (8)
Current Projects:
1. Platelet production from haematopoietic stem cells: How to enhance platelet numbers.
There is increased demand for platelet transfusions in several patient groups such as AML
patients, stem cell transplant recipients and those undergoing chemotherapy. In addition,
many patients refractory to heterologous platelet transfusions would greatly benefit from a
supply of autologous platelets produced in vitro. We have demonstrated that we can
produce platelets in vitro and that the production can be augmented by forced expression
of transcription factors (5, 6). The current project aims to increase platelet production but
over expression of the master regulator GATA-1.
2. Drug-induced immune thrombocytopenia and immune thrombocytopenia: the current

research topics in this area include:
- Elucidation of the mechanisms of drug-dependent antibody cellular damage
- Investigations of the effects of immune thrombocytopenia antibodies on megakaryocyte
differentiation and platelet biology
- Effects of antibodies on platelet apoptosis
- Mapping of the binding sites of immune thrombocytopenia antibodies on platelet
receptors
3. Heparin-induced thrombocytopenia. We have developed a small antibody that prevents

platelet destruction mediated by heparin-dependent antibodies. This project currently
continues with an animal model to test the effectiveness of this molecule. In addition we
are testing a number of peptides that may inhibit the heparin-induced antibodies binding to
platelets.
4. Transcriptional regulation: this project aims to expand our understanding of transcription

factor regulation. In particular, how SUMO modification modulates the transcriptional
activity of GATA-1, FOG-1 and FOG-2 will be studied in detail.
5. Platelet aggregation and ADP signalling. We have identified molecular targets that may
prevent platelet aggregation after ADP stimulation. We aim to map these molecules and
determine the signalling pathways that give rise to this observation. This research may
prove valuable to understand platelet aggregation and also potential inhibitors of unwanted
clotting.
30
31
Supervision
The following students have completed their PhD Thesis work in the Medicine Lab:
- Eisbacher, Michael. The regulation of megakaryocyte-specific genes by Fli-1 and GATA-1
(2003)
- Buckle, Andrew. Physical interactions of the heart : FHL2, FOG-2 and GATA-4 (2005)
- Johnson, Lacey. Molecular regulation of Megakaryopoiesis: the role of Fli-1 and IFI16 (2006)
- Philips, Alana. Molecular insights into the biological role / mechanisms of GATA-4 and FOG-
2 in normal cardiac function and in cardiac hypertrophy (2007)
- Pan, Shu. Functional studies of transcription factors GATA-1, Fli-1 and FOG-1 in
Megakaryocyte development. (2007)
- Fock, Eeling. Molecular regulation and enhancement of megakaryopoiesis and
thrombopoiesis by the p45 subunit of NF-E2. (2008)
- Tan, Terence. Differentiation and migration of Sca-1+/CD 31-cardiac side population cells in
a mouse infarction model (2009). Master’s Thesis.
- Carter, Daniel. Transcriptional regulation of cardiac development and cardiac hypertrophy
(2012)
Selected Publications
1. Eisbacher M, Khachigian LM, Khin TH, Holmes ML, Chong BH; ‘Inducible expression of
megakarocyte-specific gene glycoprotein IX is mediated through an Ets binding site and
involves upstream activation of extracellular signal-regulated kinase.’ Cell and
Differentiation, 2001; 12,435-445
2. Holmes ML, Bartle N, Eisbacher M, Chong BH. ‘Cloning and analysis of the thrombopoietin-
induced megakaryocyte-specific glycoprotein VI promoter and it's regulation by GATA-I, Fli-
1, and Sp1.’ Journal of Biological Chemistry. 2002; 277: 48333-48341
3. Hu W, Philips A, Kwok J, Eisbacher M, Chong BH. ‘Identification of nuclear import and export
signals within Fli-1: Roles of the nuclear import signals in Fli-1-dependant activation of
megakaryocyte-specific promoters.’ Molecular and Cellular Biology, 2005; 25: 3087-3108
4. Kwok JC, Perdomo J, Chong BH. Identification of a Monopartite Sequence in PU.1 Essential
for Nuclear Import, DNA-Binding and Transcription of Myeloid-Specific Genes. Journal of
Cellular Biochemistry 2007; 101:1456-74.
5. Fock EL, Yan F, Pan S, Chong BH. ‘NF-E2-mediated enhancement of megakaryocytic
differentiation and platelet production in vitro and in vivo.’ Experimental Hematology 2008;
36:78-92.
6. Perdomo J, Fock EL, Kaur G, Yan F, Khachigian LM, Jans DA, Chong BH. ‘A monopartite
Sequence is essential for p45 NF-E2 nuclear translocation, transcriptional activity and
platelet production.’ Journal of Thrombosis Haemostasis 2010; 8(11):2542-53.

32
7. Asvadi P, Ahmadi z, Chong BH. ‘Drug-induced thrombocytopenia: localization of the binding

site of GPIX-specific quinine dependant antibodies.’ Blood, 2003; 102: 1670-7
8. Liang SX, Khachigian LM, Parish CR, Davenport MP and Chong BH. ‘Drug-induced
thrombocytopenia (DITP): Development of a novel NOD/SCID mouse model to evaluate
clearance of circulating platelets by drug-dependent antibodies and the efficiency of IVRG.’
Blood 2010; 116(11):1958-60.
9. Perdomo J,Yan F, Ahmadi Z, Jiang XM, Stocker R, Chong BH. ‘Quinine-induced
thrombocytopenia: drug-dependent GPIb/IX antibodies inhibit megakaryocyte and
proplatelet production in vitro.’ Blood 2011; 117 : 5975-5986.
10. Phillips A, Kwok JC, Chong BH. ‘Analysis of the signals and mechanisms mediating nuclear
trafficking of GATA-4: Loss of DNA-binding is associated with localization in intranuclear
speckles.’ Journal of Biological Chemistry. 2007; 282: 24915-24927.
11. Liang SX, Tan TJ, Chong BH. ‘Differentiation and migration of Sca-1+/CD31- cardiac side
population cells in a murine myocardial ischemic model.’ International Journal of
Cardiology. 2010; 138: 40-49.
12. Liang SX, Khachigian LM, Ahmadi, Z, Yang M, Lui S and Chong BH. ‘In vitro and in vivo
proliferation, differentiation and migration of cardiac endothelial progenitor cells
(SCA1+/CD31+ side-population cells).’ Journal of Thrombosis and Haemostasis. 2011; 1628-
37.
13. Eisbacher M, Newton A, Holmes M, Khachigan LM, Crossley M, Chong BH. ‘The protein-
protein interaction between FLI-l and GAT A-I is crucial for expression of the megakaryoctye
specific gen glycoprotein IX.’ Blood 2001; 98: 286 (a, suppl).
14. Eisbacher M, Holmes ML, Newton A, Hogg PI, Khachigian LM, Crossley M, Chong BH.
‘Protein-protein interaction between Fli-1 and GATA-1 mediates synergistic expression of
Megakaryocyte-specific genes through cooperative DNA-binding.’ Molecular and Cellular
Biology, 2003; 23: 3427-41.
For more information see PUBLICATIONS: B H Chong.
32
33
RESEARCH GRANTS
Category I - Nationally Competitive Grants:

NHMRC Program Grants:
Program Grant NHMRC 455395.
CN Chesterman, MC Berndt, BH Chong, PJ Hogg, LM Khachigian, CR Parish, RO Stocker.
Vascular Biology: 2007-2011
$14,516,629
CN Chesterman, RK Andrews, MC Berndt, BH Chong, et al.

Vascular Biology 209618: 2001-2006
$10,000,000
CN Chesterman, BH Chong, PJ Hogg, DA Owensby, LM Khachigian

Vascular Biology 943213: 1998 – 2002
$3,066,000
NHMRC Project Grants:

Project Grant NHMRC APP1012409, RM 08796, InfoEd Ref: RG102962
BH Chong, M Davenport
Drug-induced immune thrombocytopenia Jan 2011-Dec 2013
$491,706
Project Grant NHMRC RM09942 APP1028803BH

BH Chong, C Parish
Heparin-induced thrombocytopenia and thrombosis: Better understanding of pathogenesis and
improving diagnosis and treatment. Jan 2012-Dec 2014
$631,010
Australian Research Grant

BH Chong
Role of GATA-4, FOG-2 and FHL2 in transcriptional regulation of cardiac myocyte development.
2005-2007
$240,000

34
Category II - Other competitive grants:

ANZSBT Research Grant
S-J Ho
People involved in research in transfusion medicine and science undertaken in Australia and New
Zealand. 2011
$33,000
NSW Cancer Institute

S Ramanathan
Cancer Trials Nurses and Data Manager’s Grant 2010/11
$165,360
NSW Cancer Institute

S-J Ho
Cancer Trials Nurses and Data Manager’s Grant 2010/11
$82,680
The Department of Health and Aging, Australian Government, via the Specialist Training
Program, Royal College of Pathologists of Australasia
S-H Lee
2010-2011
$46,000
NSW / ACT Morphology Training Network, Royal College of Pathologists of Australasia

P Kumar, S-H Lee, D Talaulikar
Specialist Training Program Rural Project # 325 2011-2013
$40,000
St George Medical Research Foundation Post-Graduate Scholarship

P Choi
2010
$30,000 per year
34
35
UNSW Gold Star Award

BH Chong
2010
$40,000
National Heart Foundation grant

BH Chong, RL Ward, OT Chisholm
Generation of recombinant human antiplatelet antibodies for treatment of coronary artery
disease 1999- 2001
$139,458
UNSW Medical Facility Dean’s Initiative award

BH Chong, T Brighton, J Myburg et al
2006 - 2007
$250,000
Category III – Industry and other research funding:
Industry Funded Clinical Research Projects:

− BH Chong, S Ramanathan, F Roncolato, X Badoux, S-J Ho, A Hugman, M Harvey, Principal
Investigators.
− 2010 Grant Funds: $894, 700
− 2011 Grant Funds: $ 387, 900
International Research Grants:
Singapore National Medical Research Council Grant

BH Chong
Development of platelet inhibitors for treatment of coronary heart disease 2001 – 2005
$2,264,000

36
Equipment Research Grants:
UNSW Major Research Equipment and Infrastructure Initiative

L Khaohugian, CN Chesterman, P Hogg, W Jessup, BH Chong, et al
$1,100,000
NHMRC Equipment Grant

BH Chong, S Krulas, B Allen, et al
AKTA Explorer System 2004
$65,000
NHMRC Equipment Grant

B Allen, BH Chong, P Cistulli, et al
Bio-Rad Cell Map Confocal Imaging System 2003
$151,000
36
37
COMMERCIAL FUNDING – CURRENTLY HELD BH CHONG:
TITLE / INVESTIGATORS SOURCE PERIOD FUNDS (total)
EINSTEIN VTE treatment study: Oral direct oral

factor Xa inhibitor Rivaroxaban in patients with
acute symptomatic deep vein thrombosis and Bayer / Covance 2007-2012 $440,000.00
pulmonary embolism (St George Hospital) BH
Chong.
EINSTEIN VTE treatment study: Oral direct oral
factor Xa inhibitor Rivaroxaban in patients with
acute symptomatic deep vein thrombosis and Bayer / Covance 2007-2012 $150,000.00
pulmonary embolism. (Sutherland Hospital) BH
Chong.
AMPLIFY TREATMENT: A Safety and Efficacy Trial
MS/Pfizer/PPD
Evaluating the Use of Apixaban in the Treatment $125,000.00
(Amplify 2009-12
of Symptomatic Deep Vein Thrombosis and
Treatment)
Pulmonary Embolism BH Chong
AMPLIFY EXTENSION:: A safety and efficacy trial
MS/Pfizer/PPD
evaluating the use of Apixaban for the extended
(Amplify 2008 –12 $180,000.00
treatment of deep vein thrombosis and
Extension)
pulmonary embolism BH Chong.
The Edoxaban HOKUSAI VTE Study: A Phase 3,
Randomized, Double-Blind, Double-Dummy,
Parallel-Group, Multi-Center, Multi-National
Study for the Evaluation of Efficacy and Safety of Daiichi-Sankyo
2010-2012 $60,000.00
(LMW) Heparin/ Edoxaban Versus (LMW)
Heparin/Warfarin In Subjects with Symptomatic
Deep-Vein Thrombosis and/or Pulmonary
Embolism. BH Chong
ASPIRE: Aspirin to prevent recurrent venous
thromboembolism. A multi-centre, randomised,
double-blind, placebo-controlled clinical trial
NHMRC -CTC 2003-2012 $5,000
examining the efficacy and safety of low-dose
aspirin after initial oral anticoagulation to prevent
recurrent venous thromboembolism. BH Chong
(Eltrombopag Extended Dosing Study): An
extension study of eltrombopag olamine (SB-
$85,000 for
497115-GR) in adults, with idiopathic GSK 2007-2013
2007-2012
thrombocytopenic purpura (ITP), previously
enrolled in an eltrombopag study. BH Chong

38
A Randomized, Double-blind, Placebo-controlled

Study of the JAK Inhibitor INCB018424 Tablets
Administered Orally to Subjects With Primary Incyte $48,000 for
2010-2014
Myelofibrosis, Post-Polycythemia Vera Corporation 2010-2012
Myelofibrosis or Post-Essential Thrombocythemia
Myelofibrosis. BH Chong
A Prospective, Phase IV, Open-Label, Multi-
Center Study Evaluating Changes in Bone Marrow
Morphology in Adult Subjects Receiving
$42,000 for
Romiplostim for the Treatment of Amgen 2010-2015
2010-2012
Thrombocytopenia Associated with Immune
(Idiopathic) Thrombocytopenia Purpura (ITP). BH
Chong
A global, observational, non-interventional study
collecting effectiveness, safety and quality of life $35,000 for
Alexion 2010-2015
data on patients with Paroxysmal Nocturnal 2010-2012
Haemoglobinuria (PNH) Disease. BH Chong
International ITP Registry: A Multi-centre, Chong BH:
prospective disease registry for adults diagnosed Chair, Steering
~$180,000 for
with primary immune thrombocytopenia purpura Committee. 2011-2021
2011-12
(ITP) Asia-Pacific, Middle Eastern and S American Unrestricted
countries. BH Chong grant from GSK
An Observational Study of Neutropenia in
Subjects Being Treated for Relapsed or
Amgen 2011-2015 $7,000 for 2011:
Relapsed/Refractory Multiple Myeloma. BH
Chong
38
39
PUBLICATIONS
BH CHONG
Original Peer-Reviewed Journal Publications: 2001-2011
1. Hicks C, Isaacs A, Wong R, Chong BH. ‘CXCR4 expression on transplanted peripheral blood CD34 (+)
cells: relationship to engraftment after autologous transplantation in a cohort of multiple myeloma
patients.’ Annals of Hematology. 2011; 90(5):547-55.
2. Decousus H, Tapson VF, Bergmann JF, Chong BH, Froehlich JB, Kakkar AK, Merli GJ, Monreal M,
Nakamura M, Pavanello R, Pini M, Piovella F, Spencer FA, Spyropoulos AC, Turpie AG, Zotz RB,
Fitzgerald G, Anderson FA; IMPROVE Investigators. ‘Factors at Admission Associated With Bleeding
Risk in Medical Patients.’ Chest. 2011; 139(1): 69-79.
3. Spyropoulos A, Anderson F, FitzGerald G, Décousus H,Pini M, Chong B, Zotz R, Tapson V, Froehlich J,
Monreal M, Merli G, Pavanello R, Turpie A, Nakamura M, Piovella F, Kakkar A, Spencer F, Bergmann
JF. ‘Predictive and Associative Models to Identify Hospitalized Medical Patients at Risk for Venous
Thromboembolism.’ Chest. 2011 Sep; 140(3):706-14.102.
4. Equinox Investigators. Büller HR, Destors JM, Gallus A, Prins MH, Raskob G, Charbonnier, Decousus H,
Leizorovicz A, Laporte S, Prins MH, Brandjes DP, Middeldorp S, Destors JM, Pillion G, Ceresetto JM,
Hendler H, Xavier DL, Santini F, del Carmen Gallo, Coughlin P, Chong B, et al. ‘Efficacy and safety of
once weekly subcutaneous idrabiotaparinux in the treatment of patients with symptomatic deep
venous thrombosis.’ Journal of Thrombosis Haemostasis 2011; 9(1):92-9.
5. Chen JB, Liu M, Parish CR, Chong BH, Khachigian LM. ‘Nuclear import of early growth response-1
involves importin-7 and the novel nuclear localization signal serine-proline-serine.’ International
Journal of Biochemistry and Cell Biology. 2011; 43(6):905-12.
6. Perdomo J, Yan F, Ahmadi Z, Jiang XM, Stocker R, Chong BH. ‘Quinine-induced thrombocytopenia:
drug-dependent GPIb/IX antibodies inhibit megakaryocyte and proplatelet production in vitro.’ Blood
2011; 117 : 5975-5986.
7. Liang S, Khachigian L, Ahmadi Z, Mo Y, Lui S, Chong BH. ‘In vitro and in vivo proliferation,
differentiation and migration of cardiac endothelial progenitor cells (SCA1+/CD31+side population
cells.’ Journal of Thrombosis and Haemostasis 2011; 9:1628-1637.
8. Heng LL, Caguioa P, Ng SC, Chiou T-J, Lee JW, Miyakawa Y, Tambunan K, Chong BH. ‘Chronic Adult
Primary Immune Thrombocytopenia (ITP) in the Asia-Pacific Region.’ International Journal of
Haematology. 2011; 94:142-149.
9. Chapman NH, Lazar SP, Fry M, Lassere MN, Chong BH. ‘Clinicians adopting evidence based
guidelines: a case study with thromboprophylaxis.’ BMC Health Services Research. 11: 240, 2011.
10. Warkentin TE, Greinaoher A, Gruel Y, Aster RH, Chong BH. ‘Laboratory Testing for HIT: a conceptual
framework and implications for diagnosis of HIT.’ Journal of Thrombosis Haemostasis. 2011; 9(12):
2498-2500.

40
11. Wang B, Chen JB, Santiago FS, Janes M, Kavurma MM, Chong BH, Pimanda JE, Khachigian LM.
‘Phosphorylation and Acetylation of Histone H3 and Autoregulation by Early Growth Response 1
Mediate Interleukin 1 beta Induction of Early Growth Response 1 Transcription.’ Arteriosclerosis
Thrombosis and Vascular Biology. 2010; 30(3): 536-545.
12. Liang SX, Tan TJ, Chong BH. ‘Differentiation and migration of Sca-1+/CD31- cardiac side population
cells in a murine myocardial ischemic model.’ International Journal of Cardiology. 2010; 138: 40-49.
13. Kidson-Gerber GL, Weaver J, Prasan A, Gemmell R, Chong BH. ‘Serum Thromboxane B2 compared to
five other platelet function tests for the evaluation of aspirin effect in stable cardiovascular disease.’
Heart, Lung and Circulation 2010; 19:234-242.
14. Hull RD, Schellong SM, Tapson VF, Monreal M, Samama MM, Nicol P, Vicaut E, Turpie AG, Yusen RD,
and Collaborators including Chong B. ‘EXCLAIM (Extended Prophylaxis for Venous ThromboEmbolism
in Acutely Ill Medical Patients With Prolonged Immobilization) study. Extended-duration venous
thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a
randomized trial.’ Annals of Internal Medicine 2010; 153(1):8-18.
15. Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, Lensing AW, Misselwitz F,
Prins MH, Raskob GE, Segers A, Verhamme P, Wells P, Agnelli G, Bounameaux H, Cohen A, Davidson
BL, Piovella F, Schellong S. EINSTEIN Investigators including Chong B. ‘Oral rivaroxaban for
symptomatic venous thromboembolism.’ New England Journal of Medicine 2010; 363(26):2499-510.
16. Ye JY, Chan GC, Qiao L, Lian Q, Meng FY, Luo XQ, Khachigian LM, Ma M, Deng R, Chen JL, Chong BH,
Yang M. ‘Platelet-derived growth factor enhances platelet recovery in a radiation- induced
thrombocytopenic mouse model and reduces apoptosis in megakaryocytes via its receptors and PI3-
k/Akt pathway.’ Haematologica 2010; 95(10):1745-53.
17. Liang SX, Khachigian LM, Parish CR, Chong BH. ‘Drug-induced thrombocytopenia (DITP):
Development of a novel NOD/SCID mouse model to evaluate clearance of circulating platelets by
drug-dependent antibodies and the efficiency of IVRG.’ Blood 2010; 116(11):1958-60.
18. Kuter DJ, Rummel M, Boccia R, Macik BG, Pabinger I, Selleslag D, Rodeghiero F, Chong BH, Wang X, P.
Berger DP. ‘Romiplostim or Standard of Care in Patients with Immune Thrombocytopenia.’ New
England Journal of Medicine 2010; 363(20):1889-99.
19. Liu C, Li J, Meng FY, Liang SX, Deng R, Li CK, Pong NH, Lau CP, Cheng SW, Ye JY, Chen JL, Yang ST, Yan
H, Chen S, Chong BH, Yang M. ‘Polysaccharides from the root of Angelica sinensis promotes
hematopoiesis and thrombopoiesis through the PI3K/AKT pathway.’ BMC Complement Alternative
Medicine 2010; Dec 21; 10: 79.
20. Lassen MR, Gallus A, Raskob GE, Pineo G, Chen D, Ramirez LM and Advance-3 Investigators including
Chong BH. ‘Apixaban versus Enoxaparin for Thromboprophylaxis after Hip Replacement.’ New
England Journal of Medicine 2010; 363(26):2487-98.
21. Perdomo J, Fock EL, Kaur G, Yan F, Khachigian LM, Jans DA, Chong BH. ‘A monopartite Sequence is
essential for p45 NF-E2 nuclear translocation, transcriptional activity and platelet production.’
Journal of Thrombosis Haemostasis 2010 8(11):2542-53.
40
41
22. Chong BH, Gan E, Bird R, Pidcock M, Lloyd J, Tay L, Baker R, Stone C, Maher D. ‘An open-label,
multicenter study evaluating the efficacy and safety of a new 10% liquid intravenous immunoglobulin
(Intragam® 10 NF) in patients with primary immune thrombocytopenia (ITP).’ Asia-Pacific Journal of
Oncology Hematology 2010, 2 (2): 7-12.
23. Chong BH, Chong JJH. ‘IVIg immune inhibitory activity: APC is Key.’ Blood 2010; 115 (9): 1663-1664.
24. Chong BH, Chong JJH. ‘Tregs come to the rescue.’ Blood 2010; 116 (22): 4388-4390.
25. Provan D, Stasi R, Newland AC, Blanchette VS, Bolton-Maggs P, Bussel JB, Chong BH, et al.
‘International consensus report on the investigation and management of primary immune
thrombocytopenia.’ Blood 2010; 116 (2):168-186.
26. Chong BH, JJH Chong. ‘Heparin-induced thrombocytopenia associated with fondaparinux.’ Clinical
Advances in Hematology and Oncology. 2010: 8(1): 63-65.
27. Chong B. ‘Primary immune thrombocytopenia: understanding pathogenesis is the key to better
treatments.’ Journal of Thrombosis and Haemostasis 2009; 7:319-21.
28. Chong BH, Isaacs A. ‘Heparin-Induced Thrombocytopenia: What Clinicians need to know.’ Thrombosis
and Haemostasis 2009; 101:279-83.
29. Rodeghiero F, Stasis R, Gernsheimer T, Michel M, Provan D, Arnold DM, Bussel JB, Cines DB, Chong
BH, Cooper N, Godeau B, et al. ‘Standardization of Terminology, Definitions and Outcome Criteria in
Immune Thrombocytopenic Purpura of Adults and Children: Report from an International Working
Group.’ Blood 2009; 113:2386-93.
30. Shantsila E, Lip GYH, Chong BH. ‘Heparin-Induced Thrombocytopenia: A Contemporary Clinical
Approach to Diagnosis and Management.’ Chest 2009; 135:1651-64.
31. Chapman NH, Brighton T, Harris NF, Caplan GA, Braithwaite J, Chong BH. ‘Venous Thromboembolism
Management in general practice.’ Australian Family Physician 2009; 38:36-40.
32. Chong BH, Braithwaite J, Harris MF, Fletcher JP. ‘Venous Thromboembolism – A Major Health and
Financial Burden: How can we do better to prevent this Disease?’ Medical Journal of Australia 2008;
189:134-5.
33. Behalf of the Botticelli Investigators TWC, Buller H, Deitchman D, Prins M, Segers A, Chong B.
‘Efficacy and Safety of the Oral Direct Factor Xa Inhibitor Apixaban for Symptomatic Deep Vein
Thrombosis. The Botticelli DVT Dose-Ranging Study.’ Journal of Thrombosis and Haemostasis 2008;
6:1313-8.
34. Chong BH. ‘Diagnosis of drug-induced thrombocytopenia.’ International Journal of Laboratory
Hematology. 30: 10-11 suppl 1. Jun 2008.
35. Fock E, Yan F, Pan S, Chong BH. ‘NF-E2 mediated enhancement of megakaryocytic differentiation and
platelet production in vitro and in vivo.’ Experimental Hematology. 2008; 36: 78-92.
36. Yang M, Ng MHL, Li CK, Chan PKS, Liu C, Ye JY, Chong BH. ‘Thrombopoietin levels increased in
patients with Severe Acute Respiratory Syndrome (SARS).’ Thrombosis Research. 2008; 122(4):473-7.
37. Chong BH. ‘New Paradigm in the management of Idiopathic Thrombocytopenic Purpura.’ Korean
Journal of Hematology. Vol 43, suppl3, Oct 2008, pp 52-54 148.

42
38. Chong BH, Lee S-H. ‘Management of Thromboembolism in Hematologic Malignancies.’ Seminar of
Thrombosis and Hemostasis 2007; 33:435, 48.
39. Gao R, Chen X, Lin X, Qian X, Xu W, Chong BH. ‘Effects of Notoginosideson Proliferation and
Upregulation of GR Nuclear Transcription Factor in Hematopoietic Cells.’ Acta Pharmacological Sin
2007; 28:703-11.
40. Kwok JC, Perdomo J, Chong BH. ‘Identification of a Monopartite Sequence in PU.1 Essential for
Nuclear Import, DNA-Binding and Transcription of Myeloid-Specific Genes.’ Journal of Cellular
Biochemistry 2007; 101:1456-74.
41. Phillips A, Kwok JC, Chong BH. ‘Analysis of the signals and mechanisms mediating nuclear trafficking
of GATA-4: Loss of DNA-binding is associated with localization in intranuclear speckles.’ Journal of
Biological Chemistry. 2007; 282: 24915-24927.
42. Tapson VF, Decousus H, Pini M, Chong BH, Froehlich JB, , Monreal M, Spyropoulos A, Merli GJ, Zotz
RB, Bergman J-F, Pavanello R, Turpie AGG, Nakaura M, Piovella F, Kakkar AK, Spencer FA, FitzGerarld
G, Anderson FA, for the IMPROVE Investigators. ‘Venous thromboembolism prophylaxis in acutely ill
hospital medical patients: Findings from the International Medical Prevention Registry on Venous
Thromboembolism.’ Chest. 2007; 132: 936-94,.
43. Qi JC, Wang J, Mandadi S, Roufogalis B, Madigan MC, Lai K, Yan F, Chong BH, Konecny P, Stevens RL,
Krilis SA. ‘Human and Mouse Mast Cells use the Tetraspanin CD9 as an Alternate Interleukin-16
Receptor.’ Blood 2006; 107:135-42.
44. Chong BH. ‘Pathogenesis of heparin-induced thrombocytopenia and thrombosis.’ International
angiolology. 25: 42, 2006 (suppl.).
45. Pini M, Bergmann J-F, Chong BH, Decoousus H, Froehlich JB, Kakkar AK, et al. ‘Prophylaxispractices in
acutely ill medical patients: the international medical prevention registry on venous
thromboembolism (IMPROVE).’ International angiolology. 25: 193, 2006 (suppl.).
46. Fock E, Yan F, Chong BH.‚ ‘Proplatelet production from haematopoietic stem cells enhanced by NF-E2
overexpression.’ Cytotherapy 2006; 8: Suppl. 1.
47. Aster RH, Curtis BR, Bougie DW, Dunkley S, Greinacher A, Warkentan TE, Chong BH. ‘The Scientific
and Standardisation Committee of the International Society on Thrombosis and Haemostasis.
Thrombocytopenia associated with the use of GPIIb/IIIa inhibitors: position paper on the ISTH
working group on Thrombocytopenia and GPIIb/IIIa inhibitors.‘ Journal of Thrombosis and
Haemostasis. 2006; 4: 678-679.
48. Savi P, Chong BH, Greinacher A, Gruel Y, Kelton JG, Warkentin TE, Eichler P, Meuleman D, Petitou M,
Herault JP, Cariou R, Herbert JM. ‘Effect of Fondaparinux on platelet activation in the presence of
heparin-dependent antibodies: A blinded comparative multicentre study with unfractionated
heparin.’ Blood, 2005; 105: 139-144.
49. Chong BH, Ho S-J. ‘Autoimmune thrombocytopenia.’ Journal of Thrombosis and Haemostasis. 2005;
3: SOA30.
42
43
50. Hu W, Philips A, Kwok J, Eisbacher M, Chong BH. ‘Identification of nuclear import and export signals
within Fli-1: Roles of the nuclear import signals in Fli-1-dependant activation of megakaryocyte-
specific promoters.’ Molecular and Cellular Biology, 2005; 25: 3087-3108.
51. Chan EM, Comer EM, Brown FC, Richkind KE, Holmes ML, Chong BH, Shiffman R, Zhang DE, Slovak
ML, Willman CL, Noguchi CT, Li Y, Heiber DJ, Kwan L, Chan RJ, Vance GH, Ramsey HC, Hromas RA.
‘AML1-FOG2 Fusion Protein in Myelodysplasia.’ Blood 2005; 105: 4523-6.
52. Chong BH, Brighton TA, Baker R, Thurlow P, Lee CH. ‘Once-daily enoxaparin in the outpatient setting
versus unfractionated heparin in hospital for the treatment of symptomatic deep-vein thrombosis.’
Journal of Thrombosis and Thrombolysis. 2005; 19: 173-181.
53. Chong BH, Chong JJ, Expert Rev. Cardiovas Ther 2004; 2(4): 547-559.
54. Eisbacher M, Holmes ML, Newton A, Hogg PI, Khachigian LM, Crossley M, Chong BH. ‘Protein-protein
interaction between Fli-1 and GATA-1 mediates synergistic expression of Megakaryocyte-specific
genes through cooperative DNA-binding.’ Molecular and Cellular Biology, 2003; 23: 3427-41.
55. Asvadi P, Ahmadi z, Chong BH. ‘Drug-induced thrombocytopenia: localization of the binding site of
GPIX-specific quinine dependant antibodies.’ Blood, 2003; 102: 1670-7.
56. Yang M, Li K, NG MH, Yuen PM, Fok TF, Li CK, Hogg PJ, Chong BH. ‘Thrombospondin-1 inhibits in vitro
megakaryocytopoiesis via CD36.’ Thrombosis Research, 2003; 109(1): 47-54.
57. Cheung CC, Challis 0, Fisher G, Russell SJ, Davis A, Bruce H, Watt 1, Chong BH. ‘Anti-Mta associated
with three cases of hemolytic disease of the newborn.’ Immunohematology, 2002; 18, No.2, 37-39.
58. Holmes ML, Bartle N, Eisbacher M, Chong BH. ‘Cloning and analysis of the thrombopoietin-induced
megakaryocyte-specific glycoprotein VI promoter and it's regulation by GATA-I, Fli-1, and Sp1.’
Journal of Biological Chemistry. 2002; 277: 48333-48341.
59. Rosenthal MA, Rischin 0, McArthur G, Ribbons K, Chong BH, Fareed I, Toner G, Green MD, Basser RL.
‘Treatment of the novel anti-angiogenic agent PI-88 is associated with immune-mediated
thrombocytopenia.’ Annals of Oncology. 2002; 13: 770-776.
60. Tait SA, Dong JF, Lopez JA, Dawes IW, Chong BH. ‘Site-directed mutagenesis of platelet glycoprotein
IB∞ demonstrating residues involved in the sulfation of tyrosine 276, 278, and 279.’ Blood, 2002; 99:
12, 4422-4427.
61. Chong BH, Gallus AS, Cade J, Manoharan A, Magnani H, Chesterman CN. ‘Prospective randomized
open-label comparison of danaparoid with dextran 70 in the treatment of heparin-induced
thrombocytopenia with thrombosis.’ Thrombosis and Haemostasis, 2001; 86: 1170-1175.
62. Keng TB, Chong B. ‘Heparin-induced thrombocytopenia and thrombosis syndrome: invivo cross-
reactivity with danaparoid and successful treatment with r-Hirudin.’ British Journal of Haemotology,
2001; 114,394-396.
63. Eisbacher M, Khachigian LM, Khin TH, Holmes ML, Chong BH; ‘Inducible expression of megakarocyte -
specific gene glycoprotein IX is mediated through an Ets binding site and involves upstream
activation of extracellular signal-regulated kinase.’ Cell and Differentiation, 2001; 12,435-445.

44
64. Tait AS, Cranmer SL, Jackson SP, Dawes IW, Chong,BH. ‘Phenotype changes resulting in high-affinity
binding of von Willebrand factor to recombinant glycoprotein Ib-IX: analysis of the platelet-type von
Willebrand disease mutations’, Blood, 98, 2001; No.6, 1812-1818.
65. Yang M, Li K, Lam AC, Yuen PMP, Fok TF, Chesterman CN, Chong BH. ‘Platelet derived growth factor
enhances granulopoiesis via bone marrow stromal cells.’ International Journal of Haematology, 2001;
73,327-334.
66. Suter CM, Hogg PJ, Price JT, Chong BH, Ward RL. ‘Identification and characterisation of a platelet
GPIb/V/IX-like complex on human breast cancers: implications for the metastatic process.’ Japanese
Journal of Cancer Research, 2001; 92, 1082-1092.
67. Chong BH. ‘Management of deep vein thrombosis.’ Australian Family Physician 2001; 30(3):235-240.
Other published materials (books, book chapters)

1. Chong BH, Carrie van der Weyden. ‘Deep vein thrombosis and pulmonary embolism’, in Disease Index
(Fifth Edition) Ed: Worth O, MIMS Australia, 2011.
2. Fletcher J, MacLellan D, Baker R, Chong BH, Fisher C, Flanagan D, Gallus A, Gibbs H, Matthews G,
Salam H, Stacey M and van Rij A. ‘Anticoagulant therapy in venous thromboembolism and atrial
fibrillation.’ Health Education and Management Innovations (ISBN 97809578909 6 1), Sydney 5th
Edition 2011.
3. McNeil C, Fletcher J, MacLellan D, Baker R, Chong BH, Fisher C, Flanagan D, Gallus A, Gibbs H,
Matthews G, Salam H, Stacey M and van Rij. ‘A Prophylaxis and treatment of venous
thromboembolism in patients with cancer.’ Health Education and Management Innovations. Sydney,
1st Edition. 2011.
4. Fletcher J, Baker R, MacLellan D, et al. ‘Prevention of venous thromboembolism: Best Practice
Guidelines for Australia and New Zealand.’ Health Education and Management International. 4th ed;
2009.
5. Fletcher J, Baker R, MacLellan D, Chong BH, Fisher C, Gallus A, Gibbs H, Hannan T, Matthews G,
Salam H, Stacey M and van Rij A. ‘Prevention of venous thromboembolism: Best Practice Guidelines
for Australia and New Zealand.’ Health Education and Management International (ISBN 0 9578909 0
7), Sydney 4th Edition 2008.
6. Chong, BH. ‘Heparin-induced Thrombocytopenia’, In Platelets (2nd Edition) Ed Michelson AD,
Academic Press New York. 2007.
7. Chong BH, Kidson-Gerber G. ‘Deep vein thrombosis and pulmonary embolism’, in: Disease Index
(Fourth Edition) Ed: Mathias T, MIMS Australia, (in press, 2007).
8. Chong BH, Magnani HN. ‘Danaparoid in the Treatment of Heparin-induced Thrombocytopenia, in:
Heparin-induced Thrombocytopenia’, Eds: Warkentin T, Greinacher A. 4th Edition. Marcel Dekker,
New York, 2006.
44
45
9. George JN, Chong BH, Li X. ‘Drug-induced Thrombocytopenia’, in: Hemostasis and Thrombosis: Basic
principles and clinical practice, Eds: Colman RC, Marder VJ, Clowes AW, George JN, Goldhaber SZ, 5th
Edition. Philadelphia: Lippincott Williams & Wilkins,pp 1095-1102, 2006.
10. Chong BH, Kwok J. ‘Molecular mechanisms of drug-induced thrombocytopenia.’ In Hemostasis and
Thrombosis: Basic Principles and Clinical Practice, Eds: Colman RC, Marder VJ, Clowes AW, George JN,
Goldhaber SZ, 5th Edition. Philadelphia: Lippincott Williams & Wilkins, pp 507-516, 2006.
Salam H, Stacey M and van Rij A. ‘Prevention of venous thromboembolism: Best Practice Guidelines
for Australia and New Zealand.’ Health Education and Management International (ISBN 0 9578909 0
rd
7), Sydney 3 Edition 2005.
12. Chong BH, Magnani HN. ‘Danaparoid in the treatment of heparin-induced thrombocytopenia’, in:
rd
Heparin-induced Thrombocytopenia, Eds: Warkentin T, Greinacher A. 3 Edition. Marcel Dekker,
New York, pp 371-396, 2004.
Salam H, Stacey M and van Rij A. ‘Diagnosis and Treatment of venous thromboembolism: Best
Practice Guidelines for Australia and New Zealand.’ Health Education and Management International
(ISBN 0 9578909 0 7), Sydney 2004.
14. Chong, BH. ‘Heparin-induced Thrombocytopenia’, In Platelets (First Edition) Ed Michelson AD,
Academic Press New York. Pp 571-591, 2002.
15. Chong BH, Chesterman CN. ‘Thrombocytopenia due to bone marrow disorders’, in Platelets in
Thrombotic and Non-Thrombotic Disorders: Pathophysiology, Pharmacology and Therapeutics. Eds:
Gresele P, Page C, Vermylen C, Fuster V. Cambridge University Press, Cambridge, UK, pp 528-541,
2002.
16. Chong BH, Magnani HN. ‘Danaparoid in the treatment of heparin-induced thrombocytopenia’, in:
nd
Heparin-induced Thrombocytopenia, Eds: Warkentin T, Greinacher A. 2 Edition. Marcel Dekker,
New York, pp 323-347, 2002.

46
SH LEE
Selected Peer-Reviewed Publications

1. Zini G, d’Onofrio G, Briggs C, Erber W, Lee SH, McFadden S, Yutaka N, Jou JM, Vives-Corrons JL,
Lesesve JF. ICSH recommendations for identification, diagnostic value, and quantitation of
schistocytes. International Journal of Laboratory Hematology 34(2), 107-116, 2012
2. Jou JM, Lewis SM, Briggs C, Lee SH, De La Salle B, McFadden S. ICSH review of the measurement of
the erythocyte sedimentation rate. International Journal of Laboratory Hematology. 33(2):125-32.
2011
3. Patton N, Brown G, Leung M, Bavishi K, Taylor J, Lloyd J, Lee SH, Tay L, Worthley S. Observational
study of iron overload as assessed by magnetic resonance imaging (MRI) in an adult population of
transfusion dependent patients with beta-thalassaemia. Internal Medicine Journal. 40(6), 419-426.
2010.
4. Lee SH, Erber WN, Porwit A, Tomonaga M, Peterson LC. ICSH guidelines for the standardization of
bone marrow specimens and reports. International Journal of Laboratory Hematology. 30(5):349-
364, 2008.
5. Briggs C, Carter J, Lee SH, Sandhaus L, Simon-Lopez R, Vives Corrons JL. ICSH Guideline for worldwide
point-of-care testing in haematology with special reference to the complete blood count.
International Journal of Laboratory Hematology 30(2):105-16. 2008.
6. Lee SH, Ho SJ, Thomas DT, Giri P, Lee H, Sia H, L.B.To, Sullivan TR. A partial nucleated differential cell
count of the bone marrow aspirate that is independent of peripheral blood dilution. International
Journal of Laboratory Hematology 30(6):473-479. 2008.
7. Duncan EM, Casey GJ, Fenech MP, Lerda NV, Casey CR, Rodgers SE, Lee SH, Chunilal S, Robinson K,
Lloyd JV. Partial and severe Factor XI deficiency in South Australia and the usefulness of Factor XI
mutation analysis for diagnosis. Pathology. 40(4):401-6. 2008.
8. Chong BH, Lee SH. Management of thromboembolism in hematologic malignancies. Seminars in
Thrombosis and Hemostasis. 33:435-448. 2007.
9. Lewis I, Lee SH. Physiology of haemopoiesis. Surgery, 25(1):3-9. 2006.
10. Muslahi MA, Sobieraj-Teague M, Lee SH, Roberts M. Multiple myeloma simulating Gaucher's disease.
British Journal of Haematology. 134:123. 2006.
11. Cao W, Lee SH, Lu JH. CD83 is preformed inside monocytes, macrophages and dendritic cells but it is
only stably expressed on activated dendritic cells. Biochemical Journal. 385:85-93. 2005.
12. Lee SH. Virtual microscopy: Applications to hematology education and training. Hematology. 10
Suppl 1:151-3. 2005.
13. Lee SH. Virtual microscopy: Applications to hematology. Laboratory Hematology. 11(1):38-45. 2005.
46
47
14. Oakley RE, Al Msherqi Z, Lim SK, Lee SH, Ho KT, Sutandar A, Lee CN, Lim YT. Transplantation of
autologous bone marrow-derived cells into the myocardium of patients undergoing coronary bypass.
Heart Surgery Forum. 8(5):E348-50. 2005.
15. Lock K, Zhang J, Lu J, Lee SH, Crocker PR. Expression of human CD33-related siglecs on mononuclear
phagocytes and dendritic cells. Immunobiology. 209(1-2):199-207. 2004.
16. Chng WJ, Chen J, Lim S, Chong SM, Kueh YK, Lee SH. Translocation (8;22) in cold agglutinin disease
associated with B-cell lymphoma. Cancer Genetics and Cytogenetics. 152:66–69, 2004.
17. Cao W, Bobryshev YV, Lord RS, Oakley RE, Lee SH, Lu J. Dendritic cells In the arterial wall express C1q:
Potential significance in atherogenesis. Cardiovascular Research. 15;60:175-86. 2003.
18. Zhang Y, Lu JH, van den Berghe, Lee SH. Increased incidence of spontaneous apoptosis in the bone
marrow of hyperdiploid childhood acute lymphoblastic leukaemia. Experimental Hematology.
30:333-339. 2002.
19. Lee SH, Kara UAK, Koay E, Lee MA, Lam S, Teo D. New strategies for the diagnosis and screening of
malaria. International Journal of Hematology. 76:291-3. 2002.
20. Lee MA, Tan CH, Aw LT, Tang CS, Singh M, Lee SH, Chia HP, Yap EPH. Quantitative real-time
fluorescence-based polymerase chain reaction for the detection of malaria parasites. Journal of
Clinical Microbiology. 40:4343-4345. 2002.
21. Lee SH. Applied physiology of haemopoiesis. Surgery. 20:9:ii-vi, 2002.
22. Lee SH, Chang HF, Zaaba AR, Chong SM. Simulated microscopy on a handheld personal digital
assistant (PDA). Technology and Health Care. 10(6):521-522. 2002.
23. Teh C, Le Y, Lee SH, Lu J. M-ficolin is expressed on monocytes and is a lectin binding to N-acetyl-d-
glucosamine that mediates adhesion and phagocytes of Escherichia Coli. Immunology. 101:225-32.
2000.
24. van den Berghe JA, Chen YC, Zhang Y, Kueh YK, Lee SH. Static cytometry identifies hyperdiploid
childhood acute lymphoblastic leukaemia. Cancer Genetics and Cytogenetics. 123:123-127. 2000.
25. Tan WC, Diwen Q, Liam BL, Ng TP, Lee SH, Eeden SV, D’Yachkova Y, Hogg JC. The human bone
marrow response to acute air pollution due to forest fires. American Journal of Respiratory and
Critical Care Medicine. 161. 1213-1217. 2000.
26. Lim SK, Ali A, Lim YK, Law HY, Ng I, Chung M, Lee SH. An anaemic patient with phenotypical beta-
thalassaemic trait has elevated level of structurally normal beta-globin mRNA in reticulocytes.
American Journal of Hematology. 65:243-50. 2000.

48
Other published material (book chapters)

1. Hsu D, Lee SH. Digital Imaging in Hematology. In Laboratory Hematology Practice. Eds Marchant KM,
Davis B. Wiley-Blackwell. pp707-718, 2012.
2. Lee SH. The bone marrow differential count: Uncertainties and Unknowns. Proceedings of the XXIV
World Congress of Pathology and Laboratory Medicine, 2007, Kuala Lumpur, Malaysia. Monduzzi
Editore International Proceedings Division, Bologna. Italy. pp155-159. 2007.
3. Lee SH, Chang HW. Clonality Analysis and Hypereosinophilia. In Molecular Basis of Chronic
Myeloproliferative Disorders. Eds Petrides PE, Pahl HL. Springer, Heidelberg, New York, pp 201-206.
2004.
4. Lee SH. Web based virtual microscopy: A new tool for medical education. Proceedings of the 3rd
International Conference on Technology in Teaching and Learning in Higher Education, Heidelberg,
Germany. Ed Spirou C. pp 165-168, 2003.
S RAMANATHAN
Original Peer-Reviewed Journal Publications
1. John W. Eikelboom, Robert Bird, David Blythe, Luke Coyle, Eng Gan, Michael Harvey, James Isbister,
Michael Leahy, David McIlroy, Farhad Rahimpanah, Sundra Ramanthan, Simone Strasser, Chris
Ward, Andrew Watts, Simon Towler and Qilong Yi. ‘Recombinant activated factor VII for the
treatment of life-threatening haemorrhage.’ Blood Coagulation & Fibrinolysis 14:713–717 2003.
2. S Ramanathan, J Koutts, MS Hertzberg. ‘Two cases of refractory warm autoimmune hemolytic
anemia treated with rituximab.’ American Journal of Hematology 78:123-126 2005.
3. C Hicks, A Trickett, YL Kwan, S Ramanathan. ‘The use of adjusted ideal body weight for overweight
patients undergoing HPC mobilisation for aulogous transplantation.’ DOI 10.1007/s00277-012-1523-
1, Annals of Hematology. Published Online 27 July 2012.
SJ HO
1. Kenealy M, Giri P, Filshie R, Ho SJ, Nicol A, Cowan L, Link E, Seymour JF. ‘60 Results of a phase II study
of thalidomide (Thal) and azacitidine (aza) in patients with clinically advanced myelodysplastic
syndromes (MDS).’ Leukaemia Research, May 2011:35, Supplement 1, pS22.
2. Ho SJ, Al Muslahi M. ‘Adult acute lymphoblastic leukaemia with lytic bone lesions.’ Internal Medicine
Journal 2009. 39(2):132-133.
3. Parry L, Gemmell R, Ho SJ, Chong B. ‘Assessment of quick spin centrifugation and the impact on
routine coagulation results.’ International Journal of Laboratory Hematology. Vol 30, Supplement 1,
June 2008.
48
49
4. Ho SJ, Gemmell R, Brighton. TA ’Platelet function testing in uraemic patients.’ Haematology 2008
Feb;13(1):49-58.
5. Lee SH, Ho SJ, Thomas DT, Giri P, Lee H, Sia H, To LB, Sullivan TR. ‘A partial nucleated differential cell
count of the bone marrow aspirate that is independent of peripheral blood dilution’ International
Journal of Laboratory Hematology 2008. 30(6):473-479.
6. Ho SJ, Brighton TA. ‘Ximelagatran: oral direct thrombin inhibitor.’ Vascular Health and Management,
2006, Vol 2, No 1, p49-59.
7. Chong BH, Ho SJ. ‘Autoimmune Thrombocytopenia – State of the Art.’ Journal of Thrombosis and
Haemostasis 2005, Vol 3, No 8, p1763-72.
8. Ho SJ, Manoharan. ‘A Progressive hepatic lymphoma successfully treated with regional
chemotherapy through a hepatic artery catheter’. Internal Medicine Journal, Aug 2006, Vol 36, No 8,
p538-540.
F RONCOLATO
1. Brennan, S., & Roncolato, F. (2011). ‘Novel fibrinogen (B β401Gly→Val) presents as dys- or
hypodysfibrinogenaemia due to alterations in sialic acid content.’ Thrombosis and Haemostasis
(2011: 106/3 (Sep) pp. 389–565), 551-553.
2. Mannu C, Gazzola A, Bacci F, Sabattini E, Sagramoso C, Roncolato F, Rossi M, Laginestra MA,
Sapienza MR, Agostinelli C, De Leo A, Piccioli M, Righi S, Artioli P, Chilli L, Da Pozzo G, De Biase G,
Sandri F, Pileri SA, Piccaluga PP. ‘Use of IGK gene rearrangement analysis for clonality assessment of
lymphoid malignancies: a single center experience.’ American Journal of Blood Research. 2011;
1(2):167-74. Epub 2011 Sep 12.
3. Piccaluga, P., Gazzola, A., Mannu, C., Agostinelli, C., Bacci, F., Sabattini, E., Sagramoso, C., Piva, R.,
Roncolato, F., Inghirami, G., & Pileri, S. (2011). ‘Pathobiology of anaplastic large cell lymphoma.’
Advances in Hematology. 2010:345053. Epub 2011 Feb 6.
4. Roncolato, F., Gazzola, A., Zinzani, P. L., Pileri, S. A., & Piccaluga, P. P. (2011). ‘Targeted molecular
therapy in peripheral T-cell lymphomas.’ [doi: 10.1586/ehm.11.55]. Expert Review of Hematology
2011, 4(5), 551-562.
5. Piccaluga, P. P., Gazzola, A., Mannu, C., Agostinelli, C., Bacci, F., Sabattini, E., Sagramoso, C., Piva, R.,
Roncolato, F., Inghirami, G., & A., P. S. (2010). ‘Pathobiology of Anaplastic Large Cell Lymphoma.’
Advances in Hematology, 2010:345053.
6. Roncolato F, Lee S. ‘The Utility of the Bone Marrow Trephine Biopsy in Acute Myeloid Leukemia
Following Remission Induction Therapy.’ International Journal of Laboratory Hematology 2009:101-2.

50
X BADOUX
1. Badoux, X., Bueso-Ramos, C., Harris, D., Li, P., Liu, Z., Burger, J., O'Brien, S., Ferrajoli, A., Keating, M.
J., & Estrov, Z. (2011). ‘Cross-talk between chronic lymphocytic leukemia cells and bone marrow
endothelial cells: role of signal transducer and activator of transcription 3.’ [Research Support, Non-
U.S. Gov't]. Human pathology, 42(12), 1989-2000.
2. Badoux, X. C., Keating, M. J., Wang, X., O'Brien, S. M., Ferrajoli, A., Faderl, S., Burger, J., Koller, C.,
Lerner, S., Kantarjian, H., & Wierda, W. G. (2011a). ‘Cyclophosphamide, fludarabine, alemtuzumab,
and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia’.
[Clinical Trial, Phase II Comparative Study Research Support, Non-U.S. Gov't]. Blood 2011, 118(8),
2085-2093.
3. Badoux, X. C., Keating, M. J., Wang, X., O'Brien, S. M., Ferrajoli, A., Faderl, S., Burger, J., Koller, C.,
Lerner, S., Kantarjian, H., & Wierda, W. G. (2011b). ‘Fludarabine, cyclophosphamide, and rituximab
chemoimmunotherapy is highly effective treatment for relapsed patients with CLL.’ [Clinical Trial,
Phase II]. Blood 2011, 117(11), 3016-3024.
4. Badoux, X. C., Keating, M. J., Wen, S., Lee, B. N., Sivina, M., Reuben, J., Wierda, W. G., O'Brien, S. M.,
Faderl, S., Kornblau, S. M., Burger, J. A., & Ferrajoli, A. (2011). ‘Lenalidomide as initial therapy of
elderly patients with chronic lymphocytic leukemia’. [Clinical Trial, Phase II]. Blood 2011, 118(13),
3489-3498.
5. Badoux, X. C., Keating, M. J., & Wierda, W. G. (2011). ‘What is the best frontline therapy for patients
with CLL and 17p deletion?’ [Review]. Current hematologic malignancy reports 2010/12/15 ed. 2011,
6(1), 36-46.
6. Lee, B. N., Gao, H., Cohen, E. N., Badoux, X., Wierda, W. G., Estrov, Z., Faderl, S. H., Keating, M. J.,
Ferrajoli, A., & Reuben, J. M. (2011). ‘Treatment with lenalidomide modulates T-cell
immunophenotype and cytokine production in patients with chronic lymphocytic leukemia.’
[Research Support, Non-U.S. Gov't]. Cancer 2011, 117(17), 3999-4008.
7. Parikh, S. A., Keating, M. J., O'Brien, S., Wang, X., Ferrajoli, A., Faderl, S., Burger, J., Koller, C., Estrov,
Z., Badoux, X., Lerner, S., & Wierda, W. G. (2011). ‘Frontline chemoimmunotherapy with fludarabine,
cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia.’
[Clinical Trial, Phase II Research Support, Non-U.S. Gov't]. Blood 2011, 118(8), 2062-2068.]
50
51
P CHOI
1. Choi P, Rasko J. ‘The Challenge of Investigating Thrombocytopenia.’ Medicine Today. 2011; 12(2): 26-
35
2. Choi P, Rasko J. ‘Immune Thrombocytopenia: a Diagnosis of Exclusion.’ Medicine Today. 2011; 12(3):
41-46
3. Choi P, Phillips K, Rae I. ‘High dose IV flucloxacillin may affect warfarin therapy.’ MJA 2011; 194 (11):
613
4. Choi P, Gordon JEA, Harvey M, Chong B. ‘Report on the Presentation and Outcome of ITP in a Single
st
Australian Centre.’ Accepted for publication July 1 , 2011. IMJ. In Press.
5. Choi P, Gibson J. ‘Assessment of Haemostasis – Part 1.’ Medical Observer. August 13, 2010:23-25
N CHAPMAN
1. Chapman NH, Brighton T, Harris MF, Caplan GA, Braithwaite J, Chong BH. ‘Venous thromboembolism
– management in general practice.’ Australian Family Physician 2009; 38:36-40.
C HICKS
1. C. Hicks, C. Cheung and R. Lindeman. ‘Restimulation of tumour-specific immunity in a patient with
AML following injection with B7-1 positive autologous blasts.’ Leukemia Research, 2003; 27:1051-
1061.
2. J. Case, C. Hicks, A. Trickett, YL. Kwan, A. Manoharan. ‘The Expansion of Megakaryocytes Progenitors
From CD34+ Enriched Mobilised Peripheral Blood Stem Cells is Inhibited by Flt3-L.’ Journal of
Cytokine and Interferon Research. 2006; 26;76-82.
3. C Hicks, R. Wong, A. Manoharan, YL Kwan. ‘Analysis of viable CD133+/CD34+ and CD34+ stem cell
subsets in prediction of hematopoietic engraftment in multiple patients undergoing peripheral blood
stem cell transplantation.’ May 2006; International Society of Cellular Therapy (ISCT). Berlin.
4. C. Hicks, R. Wong, A. Manoharan, Y.L. Kwan. ‘Viable CD34+/CD133+ Blood Progenitor Cell Dose as a
Predictor of Haematopoietic Engraftment in Multiple Myeloma Patients undergoing Autologous
Peripheral Blood Stem Cell Transplantation.’ Annals of Hematology. 2007; 86(8); 591-598.

52
5. Christine Hicks, Arend Isaacs, Rose Wong, Beng H Chong. ‘CXCR4 expression on transplanted
peripheral blood CD34+ cells. Relationship to engraftment after autologous transplantation in a
cohort of Multiple Myeloma patients.’ Annals of Hematology. 2011; 90; 547-555.
6. C. Hicks, A. Trickett, YL Kwan and S. Ramanathan. ‘The use of adjusted ideal body weight for
overweight patients undergoing HPC mobilisation for autologous transplantation.’ Annals of
Hematology.
R WONG

1. Hicks C, Isaacs A, Wong R, Chong BH. ‘CXCR4 expression on transplanted peripheral blood CD34+
cells: relationship to engraftment after autologous transplantation in a cohort of multiple myeloma
patients.’ Annals of Hematology. 2011 May; 90(5):547-55.
2. Hicks C, Wong R, Kwan YL, Manoharan A. ‘Viable CD34+/CD133+ blood progenitor cell dose as a
predictor of haematopoietic engraftment in multiple myeloma patients undergoing peripheral blood
stem cell transplantation.’ Annals of Haematology. 2007; 86(8):591-8.
S SMITH

1. Trickett AE, Smith S, Kwan YL. ‘Accurate calculation of blood volume to be processed by apheresis to
achieve target CD34+ cell numbers for PBPC transplantation.’ Cytotherapy. 2001;3(1):5-10.
2. Harlow FH , Brown MA , Brighton TA , Smith SL , Trickett AE , KwanYL , Davis GK . ‘Platelet activation
in the hypertensive disorders of pregnancy.’ American Journal of Obstetrics and Gynecology 2002
Sep; 187 (3): 688-95.
3. King K, Smith S, Chapman M, Sacks G. ‘Detailed analysis of peripheral blood natural killer (NK) cells in
women with recurrent miscarriage’. Human Reproduction, 2009; Vol.00, No.0 pp. 1–7.
R GEMMELL

1. Giselle Kidson-Gerber, James Weaver, Rosalie Gemmell, Ananth M. Prasan, Beng Hock Chong.
‘Serum Thromboxane B2 Compared to Five Other Platelet Function Tests for the Evaluation of Aspirin
Effect in Stable Cardiovascular Disease’ Heart, Lung and Circulation, 2010, 19 : 234–242.
52
53
2. F.H.Passam, S. Rahgozar, M.Qi, M.J.Raftery, J.W.H.Wong, K.Tanaka, Y.Ioannou, J.Y.Zhang,

R.Gemmell, J.C.Qi, B.Giannakopoulos, W.E.Hughes, P.J.Hoggs, S.A.Krilis. ‘Redox control of β2-
glycoprotein I-von Willebrand factor interaction by thioredoxin-1’ Journal of Thrombosis and
Haemostasis, 2010, 8:1-9.
3. Soheila, Rahogozar, Bill Giannakopoulos, Xiaokai Yan, Jiewei Wei, Jian Cheng Qi, Rosalie Gemmell,
Steven A. Krilis. ‘Beta-Glycoprotein I Protects Thrombin from Inhibition by Heparin Cofactor II’
Arthritis & Rheumatism, 2008, Vol 58, No 4: 1146-1155.
4. Manoharan, R. Gemmell, T. Hartwell. ‘Use of Whole Blood Platelet Lumi-Aggregometry to Optimize
Anti-Platelet therapy in Patients with Chronic Myeloproliferative Disorders.’ American Journal of
Hematology, 2006, 81: 676-683.
5. Emmanuel J. Favaloro, Jennifer Posen, Raj Ramakrishna, Soma Soltani, Simon McRae, Sarah Just,
Margaret Aboud, Joyce Low, Rosalie Gemmell, Geoff Kershaw, Robyn Coleman and Mark Dean.
‘Factor V Inhibitors: rare or not so uncommon? A multilaboratory investigation’. Blood Coagulation
and Fibrinolysis, 2004, Vol 15 No 8 637- 647.
6. Manoharan, T. Brighton, R. Gemmell, K. Lopez , S. Moran, P. Kyle. ‘Platelet Dysfunction in
Myelodysplastic Syndromes: A Clinicopathological Study’. International Journal of Haematology,
2002, 76, 272-278.
J PERDOMO

1. Perdomo, J., Yan, F. & Chong, B.H. ‘A megakaryocyte with no platelets: Anti-platelet antibodies,
apoptosis and platelet production.’ Platelets, 2012; 1-9.
2. Funnell, A.P.W., Norton, L.J., Mak, K.S., Burdach, J., Artuz, C.M., Twine, N.A., Wilkins, M.R., Power,
C.A., Hung, T.T., Perdomo, J., Koh, P., Bell-Anderson, K.S., Orkin, S.H., Fraser, S.T., Perkins, A.C.,
Pearson, R.C.M. & Crossley, M. () ‘The CACCC-binding protein KLF3/BKLF represses a subset of
KLF1/EKLF target genes and is required for proper erythroid maturation in vivo.’ Molecular and
Cellular Biology, 2012; 32, 3281-3292.
3. Perdomo J, Yan F, Ahmadi Z, Jiang XM, Stocker R, Chong BH. ‘Quinine-induced thrombocytopenia:
Drug-dependent GPIb/IX antibodies inhibit megakaryocyte and proplatelet production in vitro.’
Blood; 2011; 117(22): 5975-5986.
4. Perdomo J, Fock EL, Kaur G, Yan F, Khachigian LM, Jans DA, et al. ‘A monopartite sequence is
essential for P45 NF-E2 nuclear translocation, transcriptional activity and platelet production.’
Journal of Thrombosis and Haemostasis; 2010; 8(11): 2542–2553.
5. Kwok JC, Perdomo J, Chong BH. ‘Identification of a monopartite sequence in PU.1 essential for
nuclear import, DNA-binding and transcription or myeloid-specific genes’. Journal of Cellular
Biochemistry. 2007; 101: 1456-74.

54
6. Quinlan KG, Verger A, Kwok A, Lee SH, Perdomo J, Nardini M, Bolognesi M, Crossley M. ‘Role of the
C-terminal binding protein PXDLS motif binding cleft in protein interactions and transcriptional
repression’. Molecular and Cellular Biology. 2006; 21: 8202-13.
7. Perdomo, J., Verger, A., Turner, J., and M. Crossley. ‘Role for SUMO modification in facilitating
transcriptional repression by BKLF’ Molecular and Cellular Biology. 2005; 25: 1549-59.
8. Belinda J. Westman, José Perdomo, Jacqueline M. Matthews, Merlin Crossley and Joel P. Mackay.
‘Structural studies on a protein-binding zinc-finger domain of Eos reveal both similarities and
differences to classical zinc fingers.’ Biochemistry. 2004; 43: 13318-27.
9. Verger A, Perdomo J, and Crossley M. ‘Modification with SUMO: A Role in Transcriptional
Regulation’. EMBO Rep. 2003; 4:137-42.
Other published material (books, book chapters, reviews...

1. Alexis Verger, Jose Perdomo and Merlin Crossley. ‘CtBP and Hematopoietic Transcriptional
Regulators’; in: CtBP Family Proteins. Ed. G. Chinnadurai, Saint Louis University ISBN: 2005; 1-
58706-236-4.
54
55
PRESENTATIONS: SCIENTIFIC MEETINGS AND CONFERENCES
BH CHONG
1. Chong BH. ‘New Advances in the Treatment of ITP.’ (Invited lecture).Taiwan Haematology Society
Annual Meeting Taipei, Taiwan April, 2011.
2. Chong BH. ‘Future perspectives in ITP Management’ Corporate ITP Symposium, held in conjunction
with Taiwan Society of Haematology meeting; Taipei, Taiwan April, 2011.
3. Chong BH. ‘Update on VTE in Asia-Pacific’. (Invited lecture) XXIII The International Society on
th
Thrombosis and Haemostasis. 57 Annual SSC Meeting. Kyoto Japan July 23-28, 2011. Special
symposium, entitled “Toward Better Anticoagulant Management: Experience and evidence with
enoxaparin”.
4. Chong BH. ‘An Overview of Management of Essential Thrombocythemia’ (invited lecture).
Myeloproliferative Neoplasma Symposium, Feb 11-12, 2011. Sydney.
5. Chong BH. ‘Afternoon thrombocytopenia.’ (Invited lecture). Haematology Society of Australia (NSW
Branch) meeting, March 24, Sydney: 2011.
6. Chong BH. ‘Understanding Disease Mechanisms is the key to better treatment of immune
Thrombocytopenia.’ Australian Vascular Biology Society Annual Scientific Meeting, September 15-
18, 2011, Bowral, NSW.
7. Chong BH. ‘HIT and MIST: Fog has lifted on platelets.’ Barry Firkin Oration –Australasian Society of
Thrombosis and Haemostasis. Australia NZ Haematology Society of Australia National annual
meeting October 28-Nov 2, Sydney 2011.
8. Chong BH. ‘TPO receptor agonist treatment in ITP: Australian experience.’ (invited lecture). Australia
NZ Haematology Society of Australia National annual meeting October 28-Nov 2, Sydney 2011.
9. Feng Yan, José Perdomo, Shu Pan, Lacey Johnson, Beng Hock Chong. ‘Enhanced
Megakaryocytopoiesis and Thrombopoiesis by Mouse Megakaryocytic Progenitor Cells Over-
expressing the Transcription Factor GATA-1:’ Paper presented at Haematology Society of Australia
and New Zealand, the Australian & New Zealand Society of Blood Transfusion and the Australasian
Society of Thrombosis and Haemostasis Conference-ISHAPD, 2011, Sydney, Australia.
10. José Perdomo, Feng Yan, Zohra Ahmadi, Xing-Mai Jiang, Roland Stocker and Beng H. Chong. ‘Anti-
platelet Antibodies Induce Apoptosis, Inhibit Megakaryocyte Maturation and impair Pro-platelet
Production,’ Paper presented at Haematology Society of Australia and New Zealand, the Australian &
New Zealand Society of Blood Transfusion and the Australasian Society of Thrombosis and
Haemostasis Conference-ISHAPD, 2011, Sydney, Australia.
11. José Perdomo, Feng Yan, Zohra Ahmadi, Xing-Mai Jiang, Roland Stocker and Beng H. Chong.
‘Quinine-induced Thrombocytopenia: Drug-dependent Antibodies Inhibit Megakaryocyte and
Proplatelet Production.’ Paper presented at XXIII Congress of the International Society of Thrombosis
and Haemostasis, 2011, Japan.

56
12. Jaa Yien New, Jose Perdomo, Xing-Mai Jiang and Beng Hock Chong. ‘Heparin-Induced
Thrombocytopenia and Thrombosis - A New Emerging Therapeutic Strategy.’ Paper presented at XXIII
Congress of the International Society of Thrombosis and Haemostasis, 2011, Japan.
Thrombocytopenia and Thrombosis – Therapeutic Strategy using a Single-Chain Variable Fragment
Antibody (scFv).’ Paper presented at The St George & Sutherland Medical Symposium, Kogarah,
2011.
Thrombocytopenia and Thrombosis- A New Emerging Therapeutic Strategy.’ Paper presented at
Haematology Society of Australia and New Zealand, the Australian & New Zealand Society of Blood
Transfusion and the Australasian Society of Thrombosis and Haemostasis Conference-ISHAPD, 2011,
Sydney, Australia.
15. Chong BH. ‘Primary ITP in Adult’ (Invited lecture). Intercontinental cooperative ITP study group
satellite meeting American Society of Hematology, Orlando, USA. December 4-7, 2010.
16. Chong BH. ‘Future Perspectives in the Management of Chronic ITP.’ (Invited Lecture) 6th of Asia
Pacific Society on Thrombosis and Haemostasis, Nusa Dua, Bali, Indonesia. 13th-16th October, 2010.
17. Chong BH. ‘Platelet functions and their assessment in Myelo-proliferative Neoplasms. (Invited
Lecture) 13th ASEAN Conference of Clinical Laboratory Scientists Conference, 24-26 September 2010,
Kuala Lumpur, Malaysia.
18. Chong BH. ‘WHO Classification for Myeloproliferative Neoplasm and Its Implications’. (Invited
Lecture). 13th ASEAN Conference of Clinical Laboratory Scientists Conference, 24-26 September
2010, Kuala Lumpur, Malaysia.
19. Chong BH. ‘New Approaches to Management of Primary Immune Thrombocytopenia (ITP)’ (Keynote
lecture) Thailand ITP Symposium, Bangkok, Thailand; July 21st, 2010.
20. Chong BH. ‘International ITP registry’ (Invited lecture). Thailand ITP Symposium, Bangkok, Thailand;
July 21st, 2010.
21. Chong BH. ‘New Approaches to Management of Primary Immune Thrombocytopenia’ (Invited
lecture).Phramongkut Hospital Haematology Symposium, Bangkok, Thailand; 22nd July, 2010.
22. Chong BH. Eltrombopag, ‘Impact of New Thrombopoietin Paradigm - Future Perspectives for ITP
Management’ (Invited Lecture). Integrated Korean Haematology Society Annual Meeting May 27-29,
2010. Seoul, Korea.
23. Chong BH. ‘International consensus of ITP treatment.’ American Society of Hematology Associated
Meeting: Japanese Hematologists ITP Symposium. Orlando USA 2010.
24. Chong BH. ‘International ITP Registry.’ American Society of Hematology Associated Meeting:
Japanese Hematologists ITP Symposium. Orlando USA 2010.
25. José Perdomo, Feng Yan, Zohra Ahmadi, Xing-Mai Jiang, Roland Stocker and Beng H. Chong.
‘Proplatelet Production Is Impaired by Drug-Induced Thrombocytopenia Antibodies.’ Paper
presented at American Hematological Society, Orlando, Florida, Dec 2010.
56
57
26. Jose Perdomo and Beng H. Chong (invited lecture). ‘SUMOylation and Transcriptional Regulation’,
2010, School of Biomedical Sciences, University of Newcastle, Australia.
27. Lowinger J, Chong BH, Seale P (Chair). ‘Prescribing heparin safely in the context of VTE prophylaxis’: A
position statement of the NSW Therapeutic Advisory Group (NSW TAG) June 2008.
28. Chong BH, Kakkar AK, Tapson VF, Decousus H, Monreal M, Nakamura M, et al. ‘The influence of
previous or currently active cancer on venous thromboembolism prophylaxis prescribing practices in
acutely ill medical patients’ Journal of Thrombosis and Haemostasis. 3: P1590, 2005.
29. Tapson VF, Bergmann JF, Chong BH, Merli GJ, Nakamura M, Pavanello R et al. ‘Physician practices for
providing venous thromboembolism prophylaxis to hospitalized acutely ill medical patients: Findings
from the International Medical Prevention Registry on Venous Thromboembolism (IMPROVE).’
Journal of Thrombosis and Haemostasis. 3: P1673, 2005.
30. Zota R, Decousus H, Monreal M, Chong BH, Pavanello R, Pini M, et al for the IMPROVE Investigators.
‘Venous thromboembolism prophylaxis to acutely ill medical patients: Do perceived risk factors for
bleeding influence physicians’ practices? Findings from IMPROVE.’ Journal of Thrombosis and
Haemostasis. 3: P1099, 2005.
31. Chong BH, Zohra A, Shen MJ, Kroll H ‘Drug-induced Thrombocytopenia: Mapping of the binding Site
of the Rifampicin-dependent Antibody on GPIX.’ Journal of Thrombosis and Haemostasis.. 3: P10307,
2005.
32. Yang M, Li K, Li CK, Pong NH, Sung RYT, Chong BH, Fok TF. ‘The Effect of Chinese Danggui and PDGF
on Thrombopoiesis in Irradiated Mice’. Journal of Thrombosis and Haemostasis. 3: P1538, 2005.
33. Decousus H, Zotz R, Tapson VF, Chong BH, Froehlich JB, Pavanello R, et al. ‘Factors at admission that
are predictive of increased in-hospital bleeding in acutely ill medical patients: Findings from the
International Medical Prevention Registry On Venous Thromboembolism (IMPROVE).’ Blood. 106:
81a, 2005.
34. Monreal M, Zotz RB, Decousus H, Chong BH, Merli GJ, Pavanello R, Pini M, et al. ‘Influence of
perceived risk factors for bleeding on venous thromboembolism prophylaxis practices in acutely ill
medical patients: Findings from IMPROVE.’ Blood 106: 269a, 2005.
35. Decousus H, Tapson VF, Chong BH, Merli GJ, Kakkar AK, , Fitzgerald G for the IMPROVE Investigators.
‘The influence of advanced age and immobility on physician practices for prescribing venous
thromboembolism prophylaxis to medical patients.’ Pathophysiology of Haemostasis and
Thrombosis. 33: 131, 2004.
36. Tapson V, Froehlich JB, Piovella F, Spyropoulos AC, Decousus H, Bergmann JF, Chong BH, et al. ‘A
multinational comparison of prophylaxis practices for venous thromboembolism during medical
intensive care: Findings from IMPROVE.’ Chest. 126: 784S, 2004.
37. Tapson V, Spyropoulos AC, Froehlich JB, Decousus H, Bergmann JF, Chong BH, et al. ‘Does obesity
influence physician practices in provision of prophylaxis for venous thromboembolism? Lessons from
IMPROVE.’ Chest. 126: 783S-c-784S-c, 2004.

58
38. Tapson V, Decousus H, Bergmann JF, Chong BH, Froehlich JB, Kakkar AK, et al. ‘The International
Medical Prevention Registry on venous thromboembolism (IMPROVE): Venous thromboembolism
prophylaxis Practices in Acutely Ill Medical Patients.’ Blood 104: 488a, 2004.
39. Decousus H, Zota R, Tapson VF, Chong BH, Monreal M, Fitzgerald G, Anderson F for the IMPROVE
Investigators. ‘Incidence and risk factors for in-hospital bleeding in acutely ill medical patients:
Findings from IMPROVE.’ Blood 104: 489a, 2004.
40. Chong BH, Kakkar AK, Tapson VF, Fitzgerald G, Anderson F, et al. ‘Venous thromboembolism
prophylaxis practices in acutely ill medical patients with either previous cancer or currently active
cancer: Findings from IMPROVE.’ Blood 104: 490a, 2004.
41. FitzGerald G, Tapson VF, Spyropoulos AC, Chong BH, et al. ‘Does obesity influence physical practices
in provision of prophylaxis for venous thromboembolism? Lessons from IMPROVE.’ CHEST 126 (4):
783S-784S Suppl. 2004.
42. Chan E, Comer E, Brown F, Richkind K, Holmes M, Chong BH, et al. ‘AML1-FOG2 fusion protein in
myelodysplasia.’ Blood 104: 2900, 2004.
43. Eisbacher M, Holmes ML, Newton A, Hogg PJ, Khachigian LM, Crossley M, Chong BH. ‘Protein-protein
genes through cooperative DNA-binding.’ Molecular and Cellular Biology, 24: 5088-5088, 2004.
44. Chong BH. ‘Autoimmune thrombocytopenia.’ The proceedings of the International Haematology
Society 2004 Nagoya.
45. Chong BH. ‘Heparin induced thrombocytopenia.’ Journal of Thrombosis and Haemostasis, 1(7): 1471-
8, 2003.
46. Chong BH. ‘Qualitative Bernard Soulier syndrome: characterisation of a normally expressed but
functionally abnormal GPIb alpha.’ Journal of Thrombosis and Haemostasis, 1: OC172, July, 2003
(suppl).
47. Savi P, Chong BH, Greinacher A, Gruel Y, Kelton JG, Warkentin TE, Eichler P, Meuleman D, Petitou M,
Herault JP, Cariou R, Herbert JM. ‘Effect of Fondaparinux on platelet activation in the presence of
heparin-dependent antibodies: A blinded comparative multicentre study with unfractionated
heparin.’ Blood, 102: 319A-319A, 2003.
48. Eisbacher M, Holmes ML, Hogg P, Newton A, Khachigan L, Crossley M, Chong BH. ‘Protein-protein
genes through cooperative DNA-binding.’ Journal of Thrombosis and Haemostasis, 1: OC357, July,
2003 (suppl).
49. Anderson FA, Decousus H, Bergmann JF, Chong B, Froehlich J, Johnson J, Kakkar A, Merli G, Monreal
M, Pavanello R, Pini M, Piovella F, Spyropoulos A, Turpie AGG, Tapson V, Zotz R, for the IMPROVE
Investigators. ‘A multinational observational cohort study in hospitalized medical patients of
practices in prevention of venous thromboembolism and clinical outcomes: Findings of the
International Medical Prevention Registry on venous thromboembolism (IMPROVE).’ Journal of
Thrombosis and Haemostasis, 1(Suppl 1): P1438, 2003.
58
59
50. Decousus H, Tapson V, Chong BH, Merli GJ, Kakkar AK, FitzGerald G for the IMPROVE Investigators.
‘Immobility and advanced age: Critical factors contributing to the overall risk of venous
thromboembolism in medical patients.’ Blood 11: 56a, 2003.
51. Turner JI, Eibacher M, Johnson LN, Crossley M, Chong BH. ‘Analysis of gene regulation by Fli-1 during
megakaryopoiesis.’ Blood 102 (11): 158B-158-B, 2003.
52. Chong BH, Asvadi P, Ahmadi Z. ‘Drug-induced immune thrombocytopenia: Characterisation of the
quinine-dependant platelet antibodies.’ Blood 100: 16a, 2002 (suppl).
53. Chong BH, Asvadi P, Khin T, Ahmadi Z. ‘Structural and functional characterisation of GPIb alpha
mutations associated with Bernard Soulier Syndrome.’ Blood 100: 688a, 2002 (suppl).
54. Chong BH. ‘A randomised, prospective, multicentre study comparing the efficacy, safety and cost of
once-daily enoxaparin given at home with unfractionated heparin given in hospital in treatment of
deep-vein thrombosis.’ Blood 100: 703a, 2002 (supp1).
55. Eisbacher M, Newton A, Holmes M, Khachigan LM, Crossley M, Chong BH. ‘The protein-protein
interaction between FLI-l and GAT A-I is crucial for expression of the megakaryoctyespecific gen
glycoprotein IX.’ Blood 98: 286a, 2001 (suppl).
SJ HO
1. Kenealy M, Giri P, Filshie R, Ho SJ, Nicol A, Cowan L, Link E, Seymour J. ‘Results of a Phase-II Study of
Thalidomide (Thal) and Azacitidine (Aza) in Patients with Clinically Advanced Myelodysplastic
Syndromes (MDS)’. Paper presented at the HSANZ Annual Scientific Meeting, Sydney, Oct 2011.
2. Desa S, Sungala N, Ho SJ. ‘Evaluation of the Reticulated Haemoglobin, a New Parameter on the
Sysmex XE 2100 by Comparison with Bone Marrow Stores’. Paper presented at the HSANZ Annual
Scientific Meeting, Sydney, Oct 2011.
3. Cavanaugh, L., Gemmell, R., & Ho, S. (2010). ‘Comparison of two different plastic sodium citrate
tubes and their affect on routine coagulation results’. Paper presented at the HAA Auckland 2010.
4. Kenealy M, Seymour JF, Cowan J, Milner A, Giri P, Ho SJ et al. ‘The Tolerability of Combined Therapy
with Thalidomide and 5-Azacitidine in Patients with Advanced Myelodysplastic Syndromes. (MDS)’
Blood (ASH annual Meeting Abstracts) Nov 2009: 114: 1749.
5. Ho SJ, Dyson P, Rawling T, Stevens J, Patton N, To LB, Lewis I. ‘Mesenchymal stem cells for treatment
of steroid-resistant graft-versus-host disease’. Paper presented at the HSANZ Annual Scientific
Meeting, Hobart, Oct 2006 – Presidential Symposium and International Blood and Marrow Transplant
Research BMT Tandem Meeting, Colorado, February 2007.
6. Ho SJ, Gemmell R, Brighton TA. ‘Platelet function testing in uraemic patients.’ Paper presented at the
European Haematology Association 11th Congress, Amsterdam, June 2006.
7. Ho SJ, Manoharan A. ‘Progressive hepatic lymphoma successfully treated with regional
chemotherapy through a hepatic artery catheter’. Paper presented at the HSANZ Annual Scientific
Meeting, Sydney, October 2005.

60
8. Ho SJ, Kwan YL, Brighton TA, Manoharan A. ‘Occult chronic lymphocytic leukaemia (CLL) in patients
presenting with non-Hodgkin’s lymphoma: The “reverse” Richter’s syndrome’. Paper presented at
the HSANZ Annual Scientific Meeting, Sydney, October 2005.
9. Ho SJ, Brighton TA, Kyle P, Kwan YL. ‘What blood users know about Emergency Blood Transfusions’.
Paper presented at the HSANZ Annual Scientific Meeting, Melbourne, October 2004 and HSANZ
Society Meeting, Sydney, July 2004.
60
61
X BADOUX
1. Badoux, X. C., Keating, M. J., O'Brien, S., Wierda, W. G., Faderl, S., Estrov, Z., Pasia, M., Lerner, S.,
Sargent, R. L., Kantarjian, H. M., & Ferrajoli, A. (2011). ‘Final Analysis of a Phase 2 Study of
Lenalidomide and Rituximab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
(CLL).’ ASH Annual Meeting Abstracts Dec 2011. 980.
2. Ferrajoli, A., O'Brien, S., Wierda, W. G., Faderl, S., Badoux, X., Estrov, Z., Schlette, E., Smith, S. C.,
Ayala, A. B., Falchi, L., Calin, S., Kantarjian, H. M., & Keating, M. J. (2011). ‘Combination Therapy with
Ofatumumab and Lenalidomide in Patients with Relapsed Chronic Lymphocytic Leukemia (CLL):
Results of a Phase II Trial.’ ASH Annual Meeting Abstracts Dec 2011.
3. Badoux, X., Al-Ameri, A. M., O'Brien, S., Wierda, W. G., Burger, J. A., Faderl, S., Estrov, Z., Lerner, S.,
Keating, M. J., & Ferrajoli, A. ‘Retrospective Analysis of the Experience with Rituximab and
Methylprednisone In Elderly Patients with CLL.’ ASH Annual Meeting Abstracts Dec 2010. 116:4636.
4. Badoux, X., O'Brien, S., Wierda, W. G., Faderl, S., Estrov, Z., Yerrow, K., Kantarjian, H. M., Keating, M.
J., & Ferrajoli, A. (2010). ‘Combination of Ofatumumab and Lenalidomide In Patients with Relapsed
Chronic Lymphocytic Leukemia: Initial Results of a Phase II Trial.’ ASH Annual Meeting Abstracts Dec
2010. 116:2464.
5. Badoux, X., Wierda, W. G., O'Brien, S. M., Faderl, S., Estrov, Z., Yerrow, K. A., Keating, M. J., &
Ferrajoli, A. ‘A phase II study of lenalidomide as initial treatment of elderly patients with chronic
lymphocytic leukemia.’ ASCO Meeting Abstracts 2010. 28:6508.
6. Al-Ameri, A. A.-A., Kantarjian, H., Malik, A., Badoux, X., Andreeff, M., Quintas-Cardama, A., &
Borthakur, G. ‘Decitabine and Gemtuzumab Ozogamicin In Patients with Advanced Myelofibrosis.’
ASH Annual Meeting Abstracts Dec 2010. 116:5061.
7. Al-Ameri, A. M., Badoux, X., Ferrajoli, A., Wierda, W. G., Fayad, L., Estrov, Z., Bickel, S., Keating, M. J.,
& O'Brien, S. ‘Phase II Study of Dasatinib In Patients with Relapsed Chronic Lymphocytic Leukemia.’
ASH Annual Meeting Abstracts Dec 2010 116:4488.
8. Al-Ameri, A. M., Cortes, J. E., Kantarjian, H., Burton, E., Quintas-Cardama, A., Jabbour, E., Badoux, X.,
O'Brien, S., & Mattiuzzi, G. ‘Infectious Events In Patients with Chronic Myeloid Leukemia Treated with
Nilotinib as a Front Line Therapy and After Imatinib Failure.’ ASH Annual Meeting Abstracts Dec 2010.
116:1233.
9. Ferrajoli, A., Badoux, X., O'Brien, S., Wierda, W. G., Faderl, S., Estrov, Z., Pasia, M., Lerner, S.,
Kantarjian, H., & Keating, M. J. ‘The Combination of Lenalidomide and Rituximab Induces Complete
and Partial Responses In Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia.’ ASH
Annual Meeting Abstracts Dec 2010 116:1395.
10. Parikh, S. A., Wierda, W. G., Badoux, X., O'Brien, S. M., Ferrajoli, A., Faderl, S., Burger, J. A., Lerner, S.,
Kantarjian, H., & Keating, M. J. ‘Comparison of fludarabine (F) plus cyclophosphamide (C) versus FC
plus rituximab (R) in previously untreated Rai stage III/IV chronic lymphocytic leukaemia (CLL).’ ASCO
Meeting Abstracts 2010. 28:6519.

62
11. Tsimberidou, A. M., Wierda, W. G., Badoux, X., Wen, S., Plunkett, W., O'Brien, S. M., Kipps, T. J.,
Jones, J. A., Kantarjian, H., & Keating, M. J. ‘Evaluation of oxaliplatin, fludarabine, cytarabine, and
rituximab (OFAR) combination therapy in aggressive chronic lymphocytic leukemia (CLL) and Richter's
syndrome (RS).’ ASCO Meeting Abstracts 2010. 28:6521.
P CHOI
1. Cook C, Straube B, Choi P. ‘Houston we have a problem..... VRE BSI.’ Oral Presentation: The South
East Sydney CHN Multidisciplinary Clinical Research and Quality Forum 2011.
2. Choi P, Chong B. ‘Outcomes in Immune Thrombocytopenia (ITP): A Retrospective Audit on a Single
Tertiary Referral Centre’. "Board of Education Trainee Poster Prize." Pathology (2011) 43: S61.
3. Choi P, Gemmell R, Chong B. ‘The Frequency of Renal Impairment in Patients Suspected of Heparin
Induced Thrombocytopenia Syndrome (HIT).’ "Board of Education Trainee Poster Prize." Pathology
(2011) 43: S61.
4. Choi P, Straube B, Cook C, van der Weyden C, Ramanathan S, Taylor P. ‘Vancomycin Resistant
Enterococcus Bloodstream Infections (VRE BSI): A multi-disciplinary approach to improving safety for
patients.’ "Board of Education Trainee Poster Prize." Pathology (2011) 43: S61.
5. Choi P, Straube B, Cook C, van der Weyden C, Ramanathan S, Taylor P. ‘Vancomycin Resistant
Enterococcus Bloodstream Infections (VRE BSI): A multi-disciplinary approach to improving safety for
patients.’ Poster Presentation: The South East Sydney CHN Multidisciplinary Clinical Research and
Quality Forum 2011.
6. Choi P, Fu M, Gemmell R, Chong B. ‘The Frequency of Renal Impairment in Patients Suspected of
Heparin Induced Thrombocytopenia Syndrome (HIT).’ Abstract: International Society of Thrombosis
and Haemostasis, Kyoto 2011: P-TU-084.
7. Choi P, Chong B. ‘Outcomes in Immune Thrombocytopenia (ITP): A Retrospective Audit on a Single
Tertiary Referral Centre.’ Abstract: International Society of Thrombosis and Haemostasis, Kyoto
2011: P-WE-064.
8. Choi P, Straube B, Cook C, van der Weyden C, Ramanathan S, Taylor P. ‘Vancomycin-Resistant
Enterococci Bloodstream Infections (VRE BSI) in Haematology Inpatients (Ref: 259).’ Accepted as
Poster Presentation: HAA-ISHAPD 2011, Sydney.
9. Choi P, Chong B. ‘A Retrospective Audit on the Presentation and Treatment Free Survival of Immune
Thrombocytopenia (ITP) in a Single Centre.’ Oral Presentation: St George and Sutherland Medical
Research Symposium 2010.
10. Choi P, Chong B. ‘A Retrospective Audit on the Presentation and Treatment Free Survival of Immune
Thrombocytopenia (ITP) in a Single Centre.’ Poster Presentation: HAA 2010, Auckland.
62
63
Induced Thrombocytopenia Syndrome (HIT).’ Poster Presentation: St George and Sutherland Medical
Research Symposium 2010.
Induced Thrombocytopenia Syndrome (HIT).’ Poster Presentation: HAA 2010, Auckland.
N CHAPMAN
1. Chapman, N., Lassere, M., Clarke, M., & Chong, B. (2010). ‘Guidelines for Venous Thomboembolism
(VTE) prevention in Hospitalised Medical Patients: A Validation Pilot Study.’ Paper presented at the
Annual Meeting of the Australasian Society of Thrombosis and Haemostasis. New Zealand 2010.
2. Josephs, B., Chapman, N., & Chong, B. (2010). ‘An audit to determine the incidence of Venous
Thromboembolism (VTE) risk assessment and prophylaxis at a regional hospital in Australia.’ Paper
presented at the Annual Meeting of the Australasian Society of Thrombosis and Haemostasis. New
Zealand 2010.
3. Josephs, B., Chapman, N., Chong, B., & Johnson, J. (2010). ‘Understanding Hospital Admission
Processes in respect to consideration of venous thromboembolism risk assessment.’ Paper presented
at the Annual Meeting of the Australasian Society of Thrombosis and Haemostasis. New Zealand
2010.
R RISTUCCIA
1. Ristuccia, R. ‘Clinical Trials Management Software - InfoEd Central Network Cancer Services - Pilot
Site Experiences.’ Paper presented at the The St George & Sutherland Medical Research Symposium.
St George Hospital, Sydney, 2010.
2. Ristuccia, R. ‘Clinical Trials Management System - Experiences of a Pilot Site.’ Paper presented at the
HAA 2010 Auckland 17-20 October 2010.
C HICKS
1. Christine Hicks, Jamie Case, Annette Trickett, YL Kwan, A. Manoharan. ‘Optimising the ex vivo
expansion of megakaryocyte precursors with CFG-Mk potential from CD34+ enriched PBSC.’ Abstract.
HSANZ 2003. NZ.
2. J Case, C. Hicks, A. Trickett, YL Kwan, A Manoharan. ‘Flt3-L reduces the optimal expansion of
megakaryocytes progenitors from CD34+ enriched mobilised peripheral blood stem cells. Abstract.’
ISEH. New Orleans, USA. 2004.

64
3. S. Roman, C. Hicks, R. Wong, M. Poole, R. Lindeman. ‘Endothelial Progenitor Stem Cells.’ Abstract.
HSANZ. Melbourne. 2004.
4. Annette Trickett, Vicki Antonenas, Lisa Barrow, Mary Brun, Annabella Chang, Lisa Fava, David Ford,
Loretta Huckstepp, Christine Hicks, Geordie Zaunders, Glenn Marshall, and Ken Bradstock.
‘Development of Common Protocols for the BMT Network NSW Laboratories.’ Abstract. HSANZ.
Melbourne 2005.
5. R. Wong, A. Abdullah, C. Hicks, A. Manoharan, YL Kwan. ‘Correlation between CD34+ stem cells and
colony-forming units (CFU-GM) at time of harvest and their viability at transplantation, and
haematopoietic engraftment kinetics after peripheral blood stem cell transplantation.’ Abstract.
HSANZ, Sydney 2005.
6. C. Hicks, A. Abdullah, R. Wong, A. Manoharan, YL Kwan. ‘Viable CD133/CD34+ and CD34+ stem cell
subsets in prediction of haematopoietic engraftment in multiple myeloma patients undergoing
autologous peripheral blood stem cell transplantation.’ Abstract HSANZ. Sydney 2005.
7. C. Hicks, M. Johnstone, P. Butler, YL Kwan, A. Manoharan. ‘Comparison of Tc-99m MIBI (sestaMIBI)
uptake by transformed and multiple myeloma (MM) plasma cells.’ Abstract. HSANZ. Sydney, 2005.
8. C. Hicks, R. Wong, A. Isaacs, B. Chong. ‘CXCR4 Expression on Mobilised CD34+ Progenitor Cells.
Correlation with Haematopoietic Engraftment in Multiple Myeloma Patients undergoing Autologous
Peripheral Blood Stem Cell Transplantation.’ Abstract. ISCT. Florida 2008.
9. C. Hicks, YL Kwan, A. Trickett, and B. Chong. ‘The use of adjusted ideal body weight for overweight
patients undergoing HPC mobilisation for autologous transplantation.’ Abstract. HAA. NZ 2010.
10. Hicks C, Trickett A, Kwan YL, Ramanathan, S. ‘The use of adjusted ideal body weight for overweight
patients undergoing mobilisation for autologous transplantation.’ Abstract. EHA, London 2011.
S SMITH
1. Smith S, Kwan Y, Brighton T. ‘Case Study: A Lymphoproliferative Disorder with Two Distinct
Monoclonal B Cell Clones’. Abstract for Poster AFCG 2005.
2. Smith S, Chapman M, Sacks G. ‘Natural Killer Cell Analysis For Women With Repeated Implantation
Failure’. Abstract for Poster AFCG 2007.
3. Fay L, Smith S, Russell P, Chapman M, Sacks G. ‘NK cell analysis in women with recurrent
reproductive failure: there is a clinical correlation between peripheral blood and endometrial biopsy
samples‘. Abstract for Australian Society for Reproductive Medicine 2007.
64
65
R WONG
1. Rose Wong, Belel Ejje, Michael Harvey. ‘Detection of chromosome aberrations in multiple myeloma
by PCR – an institutional study.’ Haematology Society of Australia & New Zealand Conference,
Sydney, October 2011.
2. Rose Wong, Sundra Ramanthan, Beng H Chong. ‘The expression levels of transcription factors in
different subsets of human peripheral blood stem cells may contribute to haematopoietic
engraftment.’ Annual Meeting, International Society for Stem Cell Research, Cairns, June 2007.
3. Rose Wong, Yiu Lam Kwan, Arumugam Manoharan. ‘Changes in the expression of transcription
factors in malignant myeloma cells.’ Haematology Society of Australia & New Zealand Conference,
Hobart; October 2006.
4. Rose Wong, Alhossain Abdallah, Christine Hicks, Arumugam Manoharan and Yiu Lam Kwan.
‘Correlation between CD34 (+) stem cells and colony-forming units -GM (CFU-GM) at time of harvest
and their viability at transplantation, and haemopoietic engraftment kinetics after peripheral blood
stem cell transplantation.’ Haematology Society of Australia & New Zealand Conference, Sydney;
October 2005.
5. Christine Hicks, Rose Wong, Alhossain Abdallah, Arumugam Manoharan and Yiu Lam Kwan. ‘Viable
CD133+/CD34+ and CD34+ stem cell subsets in prediction of haematopoietic engraftment in multiple
myeloma patients undergoing autologous peripheral blood stem cell transplantation.’ Haematology
Society of Australia & New Zealand Conference, Sydney; October 2005.
R GEMMELL
1. R. Gemmell. ‘Evaluation of the HIT Alert Test for Heparin-Induced Thrombocytopenia.’ ISLH, Nice
France 2012.
2. Lisa Parry, R. Gemmell, Prof BH Chong, Dr SJ Ho. ‘Assessment of quick spin centrifugation and the
impact on routine coagulation results.’ HAA 2008.
3. R. Gemmell. ‘Platelet Function Testing by IMPACT-R in Thrombocytopaenia.’ HAA, Hobart 2006
4. R. Gemmell, S. Evans, L. Monkhouse, T. Brighton. ‘Evaluation of DiaMed Heparin/PF4 Testing For
HIT.’ ISTH 2005.
5. R. Gemmell, A. Manoharan. ‘Use of Whole Blood Platelet aggregometry to Assess the Efficacy of
Anti-Platelet Therapy in Patients with Myeloproliferative Disorders.’ HAA Scientific Meeting,
Melbourne. 2004.
6. R. Gemmell ‘Heparin Induced Thrombocytopenia and Laboratory Testing’. AIMS 2004.
7. R. Gemmell, S. Evans, T.Brighton. ‘Real-Life Evaluation of Diamed Heparin/PF4 testing for HITS’. HSA
2002.

66
J PERDOMO
1. Siong Meng Lim, Jose Perdomo, Peter Galettis and Matthew Links. Antiangiogenic effect of low-dose
paclitaxel is mediated by RhoA inactivation: A potential new mechanism. Proceedings of the AACR-
NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2011 Nov 12-16;
San Francisco, CA.
2. Feng Yan, Jose Perdomo, Shu Pan, Lacey Johnson, Beng Hock Chong. ‘Enhanced
Megakaryocytopoiesis and Thrombopoiesis by Mouse Megakaryocytic Progenitor Cells Over-
expressing the Transcription Factor GATA-1:’ Paper presented at Haematology Society of Australia
and New Zealand, the Australian & New Zealand Society of Blood Transfusion and the Australasian
Society of Thrombosis and Haemostasis Conference-ISHAPD, 2011, Sydney, Australia.
3. Jose Perdomo, Feng Yan, Zohra Ahmadi, Xing-Mai Jiang, Roland Stocker and Beng H. Chong. ‘Anti-
platelet Antibodies Induce Apoptosis, Inhibit Megakaryocyte Maturation and impair Pro-platelet
Production,’ Paper presented at Haematology Society of Australia and New Zealand, the Australian &
New Zealand Society of Blood Transfusion and the Australasian Society of Thrombosis and
Haemostasis Conference-ISHAPD, 2011, Sydney, Australia.
4. Jose Perdomo, Feng Yan, Zohra Ahmadi, Xing-Mai Jiang, Roland Stocker and Beng H. Chong.‘Quinine-
induced Thrombocytopenia: Drug-dependent Antibodies Inhibit Megakaryocyte and Proplatelet
Production.’ Paper presented at XXIII Congress of the International Society of Thrombosis and
Haemostasis, 2011, Japan.
Thrombocytopenia and Thrombosis - A New Emerging Therapeutic Strategy.’ Paper presented at XXIII
Congress of the International Society of Thrombosis and Haemostasis, 2011, Japan.
Thrombocytopenia and Thrombosis – Therapeutic Strategy using a Single-Chain Variable Fragment
Antibody (scFv).’ Paper presented at The St George & Sutherland Medical Symposium, Kogarah,
2011.
Thrombocytopenia and Thrombosis- A New Emerging Therapeutic Strategy.’ Paper presented at
Haematology Society of Australia and New Zealand, the Australian & New Zealand Society of Blood
Transfusion and the Australasian Society of Thrombosis and Haemostasis Conference-ISHAPD, 2011,
Sydney, Australia.
8. Jose Perdomo, Feng Yan, Zohra Ahmadi, Xing-Mai Jiang, Roland Stocker and Beng H. Chong.
‘Proplatelet Production Is Impaired by Drug-Induced Thrombocytopenia Antibodies.’ Paper
presented at American Hematological Society, Orlando, Florida, Dec 2010.
9. Jose Perdomo and Beng H. Chong (invited lecture). ‘SUMOylation and Transcriptional Regulation’,
2010, School of Biomedical Sciences, University of Newcastle, Australia.
66
67
10. Jose Perdomo “FOG-2 activity in cardiac cells is regulated by SUMO modification” Cardiology at the
Frontier - Development, stem cells and heart failure. Victor Chang Cardiac Research Institute,
Sydney, Australia, 2009.
11. Jose Perdomo. “SUMOylation facilitates transcriptional repression by FOG-2 in cardiac myocytes”
Conference of the Australian Society for Biochemistry and Molecular Biology (ComBio), Sydney,
Australia 2007.
12. Jose Perdomo. “SUMO Modification is Essential for the Capacity of FOG-2 to Inhibit Cardiac
Hypertrophy”. 15th International Vascular Biology Meeting, Sydney, Australia, 2007.
13. Jose Perdomo.“The Activity of FOG-2 in Cardiomyocytes is Modulated by SUMO Modification”.
Conference on the Role and Control of GATA Factors in tissue development and disease. Capri, Italy,
2008.
14. Jose Perdomo. “Transcriptional regulation by BKLF is regulated by Sumoylation”. Molecular Biology
of Cancer Conference. Institut Suisse de Recherche Expérimentale sur le Cancer (ISREC), Lausanne,
Switzerland, 2005.

68
COMMUNITY ENGAGEMENT
BH Chong:
NHMRC Project Grant assessment panel member 2008 and 2010
Member of the Board of St George Medical research Foundation and Deputy Chair, Scientific Advisory
Committee, St George Medical Research Foundation.
Member, Medical and Dental Appointments Committee, St George Hospital.
Member of Clinical Council, St George Hospital, Sydney
Chair (2005) and Member (2003-2009), Scientific and Standardisation Committee of International Society
of Thrombosis and Haemostasis (ISTH)
Co-chair, Platelet Immunology Subcommittee, International Society of Thrombosis and Haemostasis;
Council member, Asia-Pacific Society of Thrombosis and Haemostasis;
Vice-President, Australian Bid Committee and 2019 congress, International Society of Thrombosis and
Haemostasis
Member of Editorial Boards of International Journals: (1) Thrombosis Journal, (2) Asia-Pacific Journal of
Hematology and Oncology.
SH Lee:
Chair, Science and Education Committee, International Society of Haematology, Asia-Pacific Division
(ISHAPD), 1997-2011.
Member, Editorial Board, Pathology, 2000 - present
Chair, Organising Committee, 3rd Asian Colloquium on Standardisation and Harmonization in Laboratory
Medicine, Singapore, 2001
Chair, Organising Committee, 1st Asia-Pacific Medical Education Conference, Singapore 2003
Counsellor (Australia), International Society for Laboratory Hematology, 2004-2009
Program Co-Chair, ISLH 2006, Amsterdam, Netherlands, 2006
Co-Executive Director and Member, Program Committee, ISLH 2007, Miami, USA, 2007
Member, Editorial Board, International Journal of Laboratory Hematology (IJLH), 2007 – 2010
Program Co-Chair, ISLH 2008, Sydney, Australia, 2008
Member. International Editorial Advisory Board, Malaysian Journal of Pathology, 2008 - present
Member Board of Directors, International Society of Laboratory Hematology, 2009 - present
Vice-President, International Council for Standardization in Hematology, 2009 - present
Co-Chief Editor, International Journal of Laboratory Hematology, 2010 - present
68
69
BH Chong - Awards and Honours- 2010-2011

1. Chong, BH. Australasian Society of Thrombosis and Haemostasis, The Barry Firkin’s Oration award.
2. Chong, BH. Research Award from Peoples’ Republic of China to BH Chong for his contributions to
development of research and technology in Zhejiang Province, PR of China.
3. Chong, BH. Royal College of Pathologists of Australasia South-East Asia Visiting Lecturer/Professor
Award.
4. Chong BH. K Prathap Memorial Lecture Award. Malaysia College of Pathologists/ Academy of
Medicine.
X Badoux – Awards -2011

1. Badoux, X. Celgene - Future Leaders in Hematology Award for significant contributions in the field of
hematology. 2011.

70
For further information contact:
CLINICAL TRIALS UNIT

Roslyn Ristuccia 9113 2977
Ground Floor W R Pitney Clinical Sciences Building

The St George Hospital
Gray Street KOGARAH NSW 2217 AUSTRALIA
Phone: (612) 9113 1935
Fax: (612) 9113 2960
End.
70
71

HaematologyReport PDF

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

HaematologyReport PDF

Uploaded by

Copyright:

Available Formats

2001-2011

Centre for Thrombotic and

Clinical Trials Unit

Cancer Care Centre

St George Clinical School

St George Hospital --- Kogarah

Sutherland Hospital --- Caringbah

The Department of Haematology is accredited by the Royal College of Pathologists of

Clinical Excellence - Research Excellence - Laboratory Excellence

Principal Investigators are supported by a team of physicians, scientists and research

The Haematology Research Laboratory (Department of Medicine) operates from the St

Department of Haematology Research Report 2001-2011 Version 1

SEALS laboratories maintain laboratory services, which includes laboratory research

Our Mission Statement:

Making a difference in Healthcare through quality

All clinical research is conducted in accordance with the:

NHMRC National Statement on Ethical Conduct in Human Research

FROM THE DIRECTOR OF HAEMATOLOGY

The Haematology Department at St George and Sutherland

Professor Beng Hock Chong.

FROM THE DIRECTOR OF HAEMATOLOGY ....................................................................................... iii

ST GEORGE/SUTHERLAND HOSPITALS AND HEALTH SERVICES ....................................................... 1

HAEMATOLOGY ORGANISATIONAL STRUCTURE ............................................................................. 2

HAEMATOLOGISTS AND RESEARCH INTEREST................................................................................. 3

RESEARCH AREAS ............................................................................................................................. 8

CENTRE FOR THROMBOTIC AND BLEEDING DISORDERS RESEARCH ..................................... 8

INITIATION OF CTBR ITP INTERNATIONAL REGISTRY 2011.................................................. 10

HAEMATOLOGY CLINICAL TRIALS UNIT ............................................................................... 12

HAEMATOLOGY TRIALS 1997-2011 ..................................................................................... 13

SEALS LABORATORY ACTIVITIES .......................................................................................... 27

RESEARCH GRANTS ........................................................................................................................ 33

COMMERCIAL FUNDING – CURRENTLY HELD BH CHONG: .................................................. 37

PRESENTATIONS: SCIENTIFIC MEETINGS AND CONFERENCES ....................................................... 55

COMMUNITY ENGAGEMENT .......................................................................................................... 68

Department of Haematology Research Report 2001-2011 Version 1

ST GEORGE/SUTHERLAND HOSPITALS AND HEALTH SERVICES

Department of Haematology Research Report 2001-2011 Version 1

HAEMATOLOGY ORGANISATIONAL STRUCTURE

Medical Teams Nursing Research Laboratory Services

Centre for Thrombotic SEALS

Dr Sundra Flow Cytology

Clinical Nurse Basic and

Clinical Nurse Bone Marrow Morphology

Coagulation / Special Transfusion

HAEMATOLOGISTS AND RESEARCH INTEREST

Professor Beng Chong, MBBS, PhD (Syd), FRCP (Glasgow),

For more information visit:

Department of Haematology Research Report 2001-2011 Version 1

Senior Medical Staff:

Professor Szu-Hee Lee, MBBChir, PhD, FRCPE, FRCPath, FRACP,

Dr Sundra Ramanathan, MBBS, FRACP, FRCPA

Dr Ramanathan has an interest in haematological malignancies and is Medical Director of the

Dr Shir-jing Ho, MBBS, FRACP, FRCPA

Dr Fernando Roncolato, B Med FRACP FRCPA

Dr Roncolato has an interest in the management of lymphoproliferative disorders. He is a

Dr Amanda Hugman, MBBS, FRACP, FRCPA, MPhil

Dr Hugman has an interest in the management of malignant haematology and general

Department of Haematology Research Report 2001-2011 Version 1

Dr Xavier Badoux, MBBS, FRACP, FRCPA

Dr Badoux is a clinical haematologist with a research interest in the treatment of

Senior research staff

Research scientist: Zohra Ahmedi.

Manager: Sudha Pillai; Deputy Manager: Susan Smith